Disease on EC 3.4.21.22 - coagulation factor IXa

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Effects of acidosis on fetal and maternal blood coagulation: a fetal lamb model.
Acquired Immunodeficiency Syndrome
AIDS and haemophilia.
AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations.
Clinical factors associated with progression to AIDS in the Italian cohort of HIV-positive hemophiliacs. G.I.C.C. Gruppo Italiano Coagulopatie Congenite.
Correlation of antibodies to LAV/HTLV III in hemophiliacs with the use of virus-inactivated clotting factors.
Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates.
Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells.
The spectrum of human immunodeficiency virus infection in patients with factor IX deficiency (Christmas disease)
Towards gene therapy for hemophilia B.
Activated Protein C Resistance
Associations between blood coagulation markers, NT-proBNP and risk of incident heart failure in older men: The British Regional Heart Study.
Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein--a cross-sectional population survey.
Differential haemostatic risk factors for pregnancy-related deep-vein thrombosis and pulmonary embolism: a population-based case-control study.
Effects of hormone replacement on hemostasis in spontaneous menopause.
Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?
Thrombophilic risk factors in epileptic children treated with valproic Acid.
Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.
Acute Coronary Syndrome
Direct factor IXa inhibition with the RNA-aptamer pegnivacogin reduces platelet reactivity in vitro and residual platelet aggregation in patients with acute coronary syndromes.
Factor IXa as a target for pharmacologic inhibition in acute coronary syndrome.
Percutaneous coronary intervention in left main coronary artery disease in a patient with hemophilia B.
The REG-1 anticoagulation system: a novel actively controlled factor IX inhibitor using RNA aptamer technology for treatment of acute coronary syndrome.
Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study.
Adenocarcinoma
Acquired factor IX inhibitor in a patient with adenocarcinoma of the colon.
Afibrinogenemia
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
Amyloidosis
Amyloidosis associated bleeding diatheses in the surgical patient.
Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa.
Retroperitoneal amyloidosis, factor IX and X deficiency,and gastrointestinal bleeding.
[Secondary amyloidosis connected with neoplasma of urinary bladder and acquired disorders of blood coagulation. Case report]
Anaphylaxis
'DO NOT DO' RECOMMENDATIONS IN HEMOPHILIA.
Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction.
Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
Anaphylactoid reactions and nephrotic syndrome--a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers.
Anaphylaxis Following Human Prothrombin Complex Concentrate in a Child with Lupus Anticoagulant Hypoprothrombinemia Syndrome: A Cautionary Tale.
Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies.
Factor IX deficiency and anaphylaxis.
Factor IX inhibition and epitope localization of factor IX inhibitor antibodies in haemophilia B patients with anaphylactoid reactions.
Factor IX inhibitors and anaphylaxis in haemophilia B.
Factor IX inhibitors and anaphylaxis in hemophilia B.
IgE-mediated allergy and desensitization to factor IX in hemophilia B.
Immune tolerance in haemophilia: the long journey to the fork in the road.
Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure.
Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.
Inhibitors in young boys with haemophilia.
Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B.
Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice.
Plant-based oral tolerance to hemophilia therapy employs a complex immune regulatory response including LAP+CD4+ T cells.
Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis.
Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab(®) and desensitization therapy?
The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate.
Anemia
[An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment.]
Anemia, Aplastic
Aplastic anemia in a patient with factor IX deficiency.
Anemia, Hemolytic
Efficacy of several plasma components in a young boy with chronic thrombocytopenia and hemolytic anemia who responds repeatedly to normal plasma infusions.
Anemia, Hypochromic
Hematologic risk factors for stroke in Saudi children.
Anemia, Sickle Cell
Hematologic risk factors for stroke in Saudi children.
Aneurysm, False
Ulnar artery pseudoaneurysm in a patient with factor IX deficiency (hemophilia B).
Angina Pectoris
[Coronary artery bypass with extracorporeal circulation in a patient with hemophilia B]
Angina, Unstable
Abciximab for the treatment of an acute thrombotic coronary occlusion during stent implantation in a patient with severe hemophilia B.
Antiphospholipid Syndrome
Cystic adrenal lesions: focus on pediatric population (a review).
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin.
Astrocytoma
Perioperative factor IX replacement for surgical resection of a suprasellar astrocytoma in a child with severe haemophilia B.
Atherosclerosis
An algorithmic approach to peripheral artery disease in hemophilia: extrapolation of management principles from noncoagulopathic patients.
The role of clotting factor IX in the development of atherosclerosis.
Atrial Fibrillation
Activated factor IX, factor XI and tissue factor identify patients with permanent atrial fibrillation treated with warfarin who are at risk of ischemic stroke.
Autoimmune Diseases
Familial antiphospholipid antibodies and acquired circulating anticoagulants.
Bernard-Soulier Syndrome
Clinical and laboratory features of 178 children with recurrent epistaxis.
Blindness
Manic-depressive illness and linkage reanalysis in the Xq27-Xq28 region of chromosome X.
Minireview: Molecular genetics in affective illness.
Blood Coagulation Disorders, Inherited
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.
Potentially catastrophic bleeding disorders. Approach to diagnosis and management.
Rituximab for treating inhibitors in people with inherited severe hemophilia.
Viral vector-mediated gene therapy for hemophilia.
[Diagnosis and management of hemophilia].
Blood Platelet Disorders
[Serious bleeding complications caused by warfarin with international normalized ratio 2.1.]
Brain Injuries, Traumatic
Activation peptide of coagulation factor IX improves the prognosis after traumatic brain injury.
Brain Ischemia
A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage.
Breast Neoplasms
NIRCA: a rapid robust method for screening for unknown point mutations.
Relation between hemostatic parameters and prognostic/predictive factors in breast cancer.
Carcinogenesis
Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis.
Carcinoid Tumor
Christmas disease (clotting factor IX deficiency) and the presentation of a carcinoid tumour in an inguinal hernia.
Carcinoma
Factor VIIa/tissue factor-catalyzed activation of factors IX and X on a cell surface and in suspension: a kinetic study.
Human plasma and recombinant factor VII. Characterization of O-glycosylations at serine residues 52 and 60 and effects of site-directed mutagenesis of serine 52 to alanine.
Inherited bleeding disorders in dermatologic surgery.
Multi-analyte validation in heterogeneous solution by ELISA.
The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor.
Carcinoma, Basal Cell
Inherited bleeding disorders in dermatologic surgery.
Carcinoma, Hepatocellular
Active gamma-carboxylated human factor IX expressed using recombinant DNA techniques.
Enhanced binding of HLF/DBP heterodimers represents one mechanism of PAR protein transactivation of the factor VIII and factor IX genes.
Enhancement of the human factor IX expression, mediated by an intron derived fragment from the rat aldolase B gene in cultured hepatoma cells
Enhancement of the human factor IX expression, mediated by an intron derived fragment from the rat aldolase B gene in cultured hepatoma cells.
Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells.
Expression of coagulation factor IX (Christmas factor) in human hepatoma (HepG2) cell cultures after retroviral vector-mediated transfer.
Human hepatoma cell line HuH-7 is an effective cellular system to produce recombinant factor IX with improved post-translational modifications.
In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.
Novel cell lines derived from transgenic mice expressing recombinant human proteins. Transgenic hepatoma-derived cell lines.
Carcinoma, Squamous Cell
Multi-analyte validation in heterogeneous solution by ELISA.
Cardiovascular Diseases
Aptamers as Therapeutics in Cardiovascular Diseases.
Associations of coagulation factors IX and XI levels with incident coronary heart disease and ischemic stroke: the REGARDS study.
Development of aptamer oligonucleotides as anticoagulants and antithrombotics for cardiovascular diseases: current status.
Carotid Artery Injuries
A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo.
Cerebral Amyloid Angiopathy, Familial
Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa.
Cerebral Hemorrhage
Effectiveness of Factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage.
Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa.
Cholera
Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice.
Role of Small Intestine and Gut Microbiome in Plant-Based Oral Tolerance for Hemophilia.
Chronic Periodontitis
Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from Porphyromonas gingivalis.
coagulation factor ixa deficiency
A Candidate Activation Pathway for Coagulation Factor VII.
A coagulation factor IX-deficient mouse model for human hemophilia B.
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
A complete deletion of the factor IX gene and new TaqI variant in a hemophilia B kindred.
A global view on prophylaxis: possibilities and consequences.
A pelvic pseudotumor in a nonhemophilic patient: an unusual presentation.
A simple technique to reduce epistaxis and nasopharyngeal trauma during nasotracheal intubation in a child with factor IX deficiency having dental restoration.
A study of cell mediated and humoral immunity in haemophilia and related disorders.
Abnormal B-cell function in hemophiliacs treated with cryoprecipitate and factor VIII and IX concentrates.
Acquired dysfibrinogenemia in a hemophiliac with hepatoma: resolution of fibrinogen dysfunction following chemotherapy.
Acquired factor IX deficiency in the nephrotic syndrome.
Acquired factor IX deficiency. A report of two cases.
Acquired haemophilia A: errors in the diagnosis.
Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
Acute hepatitis in a patient with mild factor IX deficiency after anesthesia with isoflurane.
Acute myelogenous leukemia in a patient with severe factor IX deficiency.
Amelioration of clinical severity of similar mutations severe factor IX deficiency by coinherited thrombophilia.
An immunologic evaluation of hemophiliac patients and their wives. Relationships to the acquired immunodeficiency syndrome.
An unusual case of pleural-based tumor with life-threatening post-operative complication.
An unusual complication in a gravida with factor IX deficiency: case report with review of the literature.
Anaphylaxis Following Human Prothrombin Complex Concentrate in a Child with Lupus Anticoagulant Hypoprothrombinemia Syndrome: A Cautionary Tale.
Aortic and mitral valve replacement in a patient with hemophilia B.
Aplastic anemia in a patient with factor IX deficiency.
Arthroscopic synovectomy of the knee in hemophilia: 10-to-15 year followup.
Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies.
Bacterial endocarditis in a child with haemophilia B: risks of central venous catheters.
Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer.
Biology of bone marrow stroma.
Bleeding Disorders in Adolescents with Heavy Menstrual Bleeding: The Queensland Statewide Paediatric and Adolescent Gynaecology Service.
Carrier detection by direct gene analysis in a family with haemophilia B (factor IX deficiency).
Changes of coagulation factors IX, VIII, VII, X, and V in nephrotic syndrome.
Christmas disease: diagnosis and management of a haemorrhagic diathesis following dentofacial trauma.
Christmas factor deficiency and decreased capillary resistance in a female with haemorrhagic diathesis.
Chronic liver dysfunction in multitransfused hemophiliacs.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Clinical manifestations and management of labor and delivery in women with factor IX deficiency.
Clot waveform of APTT has abnormal patterns in subjects with COVID-19.
Coagulation abnormalities in patients with Gaucher's disease: effect of therapy.
Coagulopathy in nephrotic syndrome at the time of renal biopsy.
Combined antihaemophilic globulin and Christmas factor deficiency in haemophilia.
Combined coagulation factor VIII and factor IX deficiency (CDF8F9) in a patient from Lithuania.
Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer.
Comparison of the sensitivity of commercial APTT reagents in the detection of mild coagulopathies.
Concurrent lymphoma and hemophilia B in a pediatric patient: A case report.
Contrast venography in young haemophiliacs with implantable central venous access devices.
Coronary artery bypass grafting in a patient with haemophilia B.
Coronary bypass in a patient with hemophilia B, or Christmas disease. Case report.
Correction of factor IX deficiency in mice by embryonic stem cells differentiated in vitro.
Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
Cranial hemophilic pseudotumor associated with factor IX deficiency: case report.
Current challenges in the management of hemophilia.
Cytological mapping of the human glucose-6-phosphate dehydrogenase gene distal to the fragile-X site suggests a high rate of meiotic recombination across this site.
Delayed diagnosis of congenital factor IX deficiency (Christmas disease) in a girl with Turner's Syndrome.
Deletion of the factor IX gene as a result of translocation t(X;1) in a girl affected by haemophilia B.
Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review.
Discordance in a pair of identical twin carriers of factor IX deficiency.
Do patients with haemophilia undergoing cardiac surgery have good surgical outcomes?
Evaluation of a new concentrate for the treatment of factor IX deficiency.
Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance. Results from the College of American Pathologists Survey Program.
Evidence of a predisposing locus to bipolar disorder on Xq24-q27.1 in an extended Finnish pedigree.
Ex Vivo Stromal Cell Electroporation of Factor IX cDNA for Treatment of Hemophilia B.
Experience with the hemophiliac child in a pediatric emergency department.
Ezetimibe: A biomarker for efficacy of liver directed UGT1A1 gene therapy for inherited hyperbilirubinemia.
Factor IX and thrombosis.
Factor IX deficiency (Christmas disease).
Factor IX deficiency (haemophilia B, Christmas disease) in a crossbred dog.
Factor IX deficiency (hemophilia B) in a family of British shorthair cats.
Factor IX deficiency (hemophilia B) in a litter of Labrador retrievers.
Factor IX deficiency (hemophilia B) in a Scottish terrier.
Factor IX deficiency and anaphylaxis.
Factor IX deficiency and bleeding in a patient with Sheehan's syndrome.
Factor IX deficiency and frugal method of analysis.
Factor IX deficiency and prolonged bleeding time.
Factor IX deficiency in an Alaskan Malamute.
Factor IX deficiency in Gaucher disease. An in vitro phenomenon.
Factor IX deficiency in liver disease.
Factor IX deficiency in nephrosis.
Factor IX deficiency in the nephrotic syndrome.
Factor IX deficiency in the nephrotic syndrome: studies with prothrombin complex concentrate.
Factor IX of the blood coagulation system: a review.
Fatal hemorrhagic diathesis associated with mild factor IX deficiency in pl/J mice.
Female factor IX deficiency due to maternally inherited X-inactivation.
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
Gene therapy for bleeding disorders.
Gene Therapy for Hemophilia.
Gene therapy in an era of emerging treatment options for hemophilia B.
Germline mosaicism resulting in the transmission of severe hemophilia B from a grandfather with a mild deficiency.
Group B streptococcal polyarthritis complicating hemophilia B.
Haemophilia B Leyden arising de novo by point mutation in the putative factor IX promoter region.
Haemorrhage and factor IX deficiency in pituitary insufficiency.
Haemorrhage in upper cervical cord: an unusual manifestation in moderate haemophilia patients who ride motorbikes.
Health care resource utilization and cost burden of hemophilia B in the United States.
Heat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.
Hematologic risk factors for stroke in Saudi children.
Hemophilia a and hemophilia B: different types of diseases?
Hemorrhage involving the upper airway in hemophilia.
Hemorrhagic diathesis in a carrier of hemophilia B.
Hemorrhagic tonsillitis.
Hepatic gene therapy for haemophilia B.
Hereditary ring sideroblastic anaemia and Christmas disease in a Swedish family.
HIV-1 infection in haemophilia.
Human coagulation factor IX: a systematic review of its characteristics.
Human factor IX corrects the bleeding diathesis of mice with hemophilia B.
Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate.
Human factor IXLincoln Park: a molecular characterization.
Human plasma fibrinogen measurement derived from activated partial thromboplastin time clot formation.
Hypercalcemia associated with normal 1,25-dihydroxyvitamin D concentrations in a neonate with factor IX deficiency.
IgE-mediated allergy and desensitization to factor IX in hemophilia B.
Immune reactive factor IX in acquired factor IX deficiency.
Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals.
Immunoassays of factor IX antigen using monoclonal antibodies.
Immunologic status of hemophilia patients treated with cryoprecipitate or lyophilized concentrate.
Implantable venous access devices in children with hemophilia: a report of low infection rates.
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
Increased thrombin generation in a child with a combined factor IX and protein C deficiency.
Inherited bleeding disorders in dermatologic surgery.
Inhibitor development in an elderly patient with severe factor IX deficiency being treated with ALPROLIX, a recombinant factor IX Fc fusion protein.
Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
Integration-deficient lentiviral vectors expressing codon-optimized R338LhFIX restore normal hemostasis in hemophilia B mice.
Intracranial meningioma in factor IX deficiency.
Intraosseous pseudotumour in a child with mild hemophilia B: report of a rare case and brief review of literature.
Intraspinal hematomas in hemophilia.
Iron studies in hemophilia.
Is haemophilia B less severe than haemophilia A?
Knee arthroplasty in hemophilic arthropathy.
Living donor liver transplantation from an asymptomatic donor with mild coagulation factor IX deficiency: report of a case.
Magnetic Resonance Imaging of Mandibular Hemophilic Pseudotumor Associated With Factor IX Deficiency: Report of Case With Review of Literature.
Management of joint bleeding in hemophilia.
Medical management of extensive spinal epidural hematoma in a child with factor IX deficiency.
Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B.
Mesenteric venous thrombosis.
Moderate hemophilia B Leyden: identification by polymerase chain reaction, sequencing, and oligomer restriction.
Molecular analysis of 76 Chinese hemophilia B pedigrees and the identification of 10 novel mutations.
Molecular analysis of hemophilia B in Poland: 12 novel mutations of the factor IX gene.
MonoFIX-VF, a new mono-component factor IX concentrate: a single-centre continuous-infusion study.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural).
Neurofibromatosis, factor IX deficiency, and rhabdomyosarcoma.
Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.
Novel missense mutations in two patients with factor XI deficiency (Val271Leu and Tyr351Ser) and one patient with combined factor XI and factor IX deficiency (Phe349Val).
Occult factor IX deficiency complicating the removal of third molars.
Off-pump myocardial revascularization in a diabetic patient with severe hemophilia B and impaired left ventricular function: hematological and operative strategies.
Orthotopic liver transplantation totally corrects factor IX deficiency in hemophilia B.
Orthotropic live transplantation for cirrhosis from hepatitis C virus leads to correction of factor IX deficiency allowing for ankle arthroplasty without factor replacement in a patient with moderate haemophilia B.
Outcomes in total elbow arthroplasty in patients with haemophilia at the University of California, San Francisco: a retrospective review.
Percutaneous liver biopsy in hemophiliac children with chronic hepatitis C virus infection.
Perioperative management of coronary artery bypass surgery in a patient with factor IX deficiency.
Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs.
Plasma support for surgery in a premature infant with factor IX deficiency.
Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources.
Possible association between cytomegalovirus infection and gastrointestinal bleeding in hemophiliac patients.
Potentially catastrophic bleeding disorders. Approach to diagnosis and management.
Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey.
Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.
Prophylaxis in factor IX deficiency product and patient variation.
Pseudotumor in a patient with factor IX deficiency.
Pseudotumor of the Mandible as First Presentation of Hemophilia in a 2-Year-Old Male: A Case Report and Review of Jaw Pseudotumors of Hemophilia.
Repair of ventricular septal defect and aortic regurgitation associated with severe hemophilia B.
Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors.
Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis.
Sensitivity of the reaction time of the resonance thrombogram for factor VIII:C and factor IX deficiencies in the blood of dogs with haemophilia A or B.
Sensitivity of three activated partial thromboplastin time reagents to coagulation factor deficiencies.
Severe factor VIII and factor IX deficiency in females.
Skeletal muscle-specific expression of human blood coagulation factor IX rescues factor IX deficiency mouse by AAV-mediated gene transfer.
Somatic mosaicism and female-to-female transmission in a kindred with hemophilia B (factor IX deficiency).
Spectrum of hereditary coagulation factor deficiencies in eastern province, Saudi Arabia.
Subperiosteal orbital hemorrhage as initial manifestation of Christmas disease (factor IX deficiency).
Successful multi-modal immune tolerance induction for factor IX deficiency with inhibitors and allergic reactions.
Surgical excision of hemophilic pseudotumor of the ilium.
Surgical management of musculoskeletal involvement in hemophilic patients.
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.
The Christmas factor deficiency in coumarin therapy.
The Effect of Danazol Treatment on Factor IX Deficiency in Cats.
The female carrier of haemophilia--a problem for the anaesthetist.
The human genes for hemophilia A and hemophilia B flank the X chromosome fragile site at Xq27.3.
The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
The molecular genetics of hemophilia A and B in man. Factor VIII and factor IX deficiency.
The Pennsylvania hemophilia program 1973-1978.
The prevalence of AIDS-associated oral lesions in a cohort of patients with hemophilia.
The spectrum of human immunodeficiency virus infection in patients with factor IX deficiency (Christmas disease)
The treatment of flexion contracture of the knee using the Ilizarov technique in a child with haemophilia B.
The use of epsilon-aminocaproic acid for the management of hemophilia in dental and oral surgery patients.
Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations.
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
Treatment modalities for inherited factor IX deficiency and the implications of inherited bleeding disorders.
Treatment of a patient with factor IX deficiency (hemophilia B) with coronary bypass surgery.
Two distinct mutations cause severe hemophilia B in two unrelated canine pedigrees.
Type IV Ehlers Danlos syndrome and factor IX deficiency: a case report.
Ulnar artery pseudoaneurysm in a patient with factor IX deficiency (hemophilia B).
Use of the activated partial thromboplastin time for the diagnosis of congenital coagulation disorders: problems and possible solutions.
Variant of factor IX deficiency in female with 45, X Turner's syndrome.
[A case of hypopituitarism complicated with the factor IX deficiency]
[Acquired coagulation factor IX deficiency in a patient with idiopathic nephrotic syndrome]
[Association of von Willebrand's disease and factor IX deficiency in males and females of a family]
[Case of Christmas factor deficiency.]
[Cases of Christmas factor deficiency in 3 patients in one family.]
[Christmas factor deficiency during treatment with dicumarol and heparin.]
[Congenital factor IX deficiency (Christmas), hemophilia B.]
[Congenital haemorrhagic diseases].
[Contribution to the study of Christmas factor deficiency in children.]
[Coronary artery bypass with extracorporeal circulation in a patient with hemophilia B]
[Factor IX deficiency, Christmas disease, in two brothers.]
[Factor IX deficiency.]
[Hemophilia B (factor IX deficiency) with concomitant factor XII degradation in a male crossbreed cat]
[Hemorrhagic parapneumonic effusion in a 64 year-old patient as the first symptom of hemophilia B]
[Microspherocytosis associated with factor IX deficiency]
[Pancytopenia and acquired factor IX deficiency in patient with Sheehan's syndrome]
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
[Studies on hemophilia in Poland. II. AHG & Christmas factor deficiency with prolonged bleeding time (vascular hemophilia A & B).]
[Thrombocytopenia-thrombocytopathy complex associated with factor IX deficiency in an Arab boy: diagnostic difficulties]
[Variants of factor IX deficiency]
coagulation factor viia deficiency
Assessing efficacy and therapeutic claims in emerging indications for recombinant factor VIIa: regulatory perspectives.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
Determinants of coagulation activation in humans.
Determinants of plasma factor VIIa levels in humans.
Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds.
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Treatment of factor XI inhibitor using recombinant activated factor VIIa.
coagulation factor xa deficiency
Congenital bleeding disorders of the vitamin K-dependent clotting factors.
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
Liver transplantation for haemophiliacs with hepatitis C cirrhosis.
coagulation factor xia deficiency
Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice.
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
In vitro evaluation of factor IX as novel treatment for factor XI deficiency.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Novel missense mutations in two patients with factor XI deficiency (Val271Leu and Tyr351Ser) and one patient with combined factor XI and factor IX deficiency (Phe349Val).
Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activation.
The lipoprotein-associated coagulation inhibitor.
The use of epsilon-aminocaproic acid for the management of hemophilia in dental and oral surgery patients.
[Menorrhagia and inherited disorders of coagulation]
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
coagulation factor xiia deficiency
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
[Hemopericardium in hypodermosis in a child with partial factor IX and factor XII deficiencies]
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
Color Vision Defects
Evidence of a predisposing locus to bipolar disorder on Xq24-q27.1 in an extended Finnish pedigree.
Linkage analysis of bipolar illness with X-chromosome DNA markers: a susceptibility gene in Xq27-q28 cannot be excluded.
Colorectal Neoplasms
miR?647 and miR?1914 promote cancer progression equivalently by downregulating nuclear factor IX in colorectal cancer.
Congenital Abnormalities
Congenital defect of Christmas factor (P.T.C.) I. Haemophilia B in seven male patients.
Congenital defect of Christmas factor (P.T.C.). II. Communication on a female case.
Hemophilic arthropathy of the foot and ankle.
IIlizarov external fixator for bilateral severe flexion deformity of the knee in haemophilia: case report.
Congenital Disorders of Glycosylation
Thrombotic complications in patients with PMM2-CDG.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model.
Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes.
Thrombotic complications in patients with PMM2-CDG.
Coronary Artery Disease
Coronary artery bypass grafting in a patient with haemophilia B.
Coronary bypass in a patient with hemophilia B, or Christmas disease. Case report.
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis.
Coronary Occlusion
Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.
Cranial Nerve Diseases
Cranial neuropathy and bone involvement in primary systemic amyloidosis.
Cystic Fibrosis
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer.
Deletion and insertion mutations in short tandem repeats in the coding regions of human genes.
Sequences within the coding regions of clotting factor VIII and CFTR block transcriptional elongation.
Disseminated Intravascular Coagulation
A test method for the absence of thrombogenicity in factor IX complex.
Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models.
Disseminated intravascular coagulation after factor IX complex resolved using purified factor IX concentrate.
Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery.
Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy.
Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
[Substitution treatment of hemophilia a and b]
Ehlers-Danlos Syndrome
Type IV Ehlers Danlos syndrome and factor IX deficiency: a case report.
Epilepsy
Serum Exosomal Proteins F9 and TSP-1 as Potential Diagnostic Biomarkers for Newly Diagnosed Epilepsy.
Epistaxis
A simple technique to reduce epistaxis and nasopharyngeal trauma during nasotracheal intubation in a child with factor IX deficiency having dental restoration.
Erythema Infectiosum
Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate.
Factor VII Deficiency
Clinical and laboratory features of 178 children with recurrent epistaxis.
Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
Determinants of coagulation activation in humans.
Determinants of plasma factor VIIa levels in humans.
Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds.
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Treatment of factor XI inhibitor using recombinant activated factor VIIa.
Factor X Deficiency
Congenital bleeding disorders of the vitamin K-dependent clotting factors.
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
Liver transplantation for haemophiliacs with hepatitis C cirrhosis.
Factor XI Deficiency
Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice.
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
In vitro evaluation of factor IX as novel treatment for factor XI deficiency.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Novel missense mutations in two patients with factor XI deficiency (Val271Leu and Tyr351Ser) and one patient with combined factor XI and factor IX deficiency (Phe349Val).
Severe factor XI deficiency caused by a Gly555 to Glu mutation (factor XI-Glu555): a cross-reactive material positive variant defective in factor IX activation.
The lipoprotein-associated coagulation inhibitor.
The use of epsilon-aminocaproic acid for the management of hemophilia in dental and oral surgery patients.
[Menorrhagia and inherited disorders of coagulation]
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
Factor XII Deficiency
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
[Hemopericardium in hypodermosis in a child with partial factor IX and factor XII deficiencies]
[Review of patients studied for coagulopathy in a Hematology/Oncology unit].
Fibrosarcoma
Construction and high expression of retroviral vector with human clotting factor IX cDNA in vitro.
Fragile X Syndrome
Close linkage of fragile X-mental retardation syndrome to haemophilia B and transmission through a normal male.
Evidence against close linkage of the loci for fraXq of Martin-Bell syndrome and for factor IX.
Genetic mapping of DNA segments relative to the locus for the fragile-X syndrome at Xq27.3.
The genetic distance between the coagulation factor IX gene and the locus for the fragile X syndrome: clinical implications.
Gaucher Disease
Coagulation abnormalities in patients with Gaucher's disease: effect of therapy.
Factor IX deficiency in Gaucher disease. An in vitro phenomenon.
Genetic Diseases, Inborn
A method to estimate effects of amino acid substitutions in blood coagulation factor IX from hemophilia B patients.
Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.
Developments in the treatment of hemophilia B: focus on emerging gene therapy.
Ex Vivo Stromal Cell Electroporation of Factor IX cDNA for Treatment of Hemophilia B.
Gene therapy for hemophilias: the end of phenotypic testing or the start of a new era?
Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter.
Inhibitors in haemophilia: what have we learned from registries? A systematic review.
Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.
Orthopaedic and surgical features in the management of patients with haemophilia.
Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.
Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors.
Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy.
Genetic Diseases, X-Linked
Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.
Glaucoma
Ocular bleeding in an undiagnosed hemophiliac neonate causing irreversible loss of vision: A case report with review of the literature.
Glioblastoma
Nuclear factor IX promotes glioblastoma development through transcriptional activation of Ezrin.
Glioma
Nuclear factor IX promotes glioblastoma development through transcriptional activation of Ezrin.
Glomerulonephritis, Membranous
Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Evidence of a predisposing locus to bipolar disorder on Xq24-q27.1 in an extended Finnish pedigree.
Manic-depressive illness and linkage reanalysis in the Xq27-Xq28 region of chromosome X.
Glucosephosphate Dehydrogenase Deficiency
Evidence of a predisposing locus to bipolar disorder on Xq24-q27.1 in an extended Finnish pedigree.
Manic-depressive illness and linkage reanalysis in the Xq27-Xq28 region of chromosome X.
Hemarthrosis
'DO NOT DO' RECOMMENDATIONS IN HEMOPHILIA.
A new treatment strategy for hemophilia B: incorporation of factor IX into red cell ghosts.
Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis.
Declining trends in invasive orthopedic interventions for people with hemophilia enrolled in the Universal Data Collection program (2000-2010).
Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.
Management of joint bleeding in hemophilia.
Orthotopic liver transplantation in hemophilia B: a case report.
Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice.
[Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)]
Hematologic Diseases
[Hemophilia B; two familial case of blood disease due to deficiency of a new coagulation factor, Christmas factor.]
Hematoma, Subdural
Acquired hemophilia first manifesting as life-threatening intracranial hemorrhage: case report.
Hematuria
'DO NOT DO' RECOMMENDATIONS IN HEMOPHILIA.
Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
Hemoperitoneum
Percutaneous liver biopsy in hemophiliac children with chronic hepatitis C virus infection.
Replacement therapy for congenital Factor X deficiency.
Hemophilia A
"Primary prophylaxis" with rFVIIa in a patient with severe haemophilia a and inhibitor.
'DO NOT DO' RECOMMENDATIONS IN HEMOPHILIA.
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
A case of heel reconstruction with a reverse sural artery flap in a hemophilia B patient.
A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
A global view on prophylaxis: possibilities and consequences.
A longitudinal study of immunological status in Chinese haemophiliacs: importance of the heat viral inactivation of factor concentrates. I. Immunological associations with the consumption of factor concentrates.
A MicroRNA-regulated and GP64-pseudotyped Lentiviral Vector Mediates Stable Expression of FVIII in a Murine Model of Hemophilia A.
A mouse model of in utero transplantation.
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.
A mutation adjacent to the beta cleavage site of factor IX (valine 182 to leucine) results in mild haemophilia Bm.
A pelvic pseudotumor in a nonhemophilic patient: an unusual presentation.
A study of cell mediated and humoral immunity in haemophilia and related disorders.
A study of reported factor IX use around the world.
A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres.
AAV vectors for hemophilia B gene therapy.
AAV-mediated gene transfer for hemophilia.
Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis.
Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy.
Activated factor IX complex in treatment of surgical cases of hemophilia A with inhibitors.
Adeno-associated virus-mediated gene transfer for hemophilia B.
Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity.
Adherence to prophylactic infusions of factor VIII or factor IX for haemophilia.
Advances in Gene Therapy for Haemophilia.
Advances in gene therapy for hemophilia: basis, current status, and future perspectives.
Advances toward gene therapy for hemophilia at the millennium.
Alternative strategies for gene therapy of hemophilia.
Alternative therapies for the management of inhibitors.
An algorithmic approach to peripheral artery disease in hemophilia: extrapolation of management principles from noncoagulopathic patients.
An immunologic evaluation of hemophiliac patients and their wives. Relationships to the acquired immunodeficiency syndrome.
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
An immunological method for detection of the carrier of hemophilia B.
An insertion within the factor IX gene: hemophilia BEl Salvador.
An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia.
An Unusual Presentation of Hemophilia A: Pseudotumor of Distal End Radius-Masquerading as Giant Cell Tumor.
Animal models of hemophilia.
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease undergoing minor oral surgery or dental extractions.
Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations.
Apheresis.
Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
Aptamer-antibody dual probes on single-walled carbon nanotube bridged dielectrode: Comparative analysis on human blood clotting factor.
Assessing risk factors: prevention of inhibitors in haemophilia.
Assessment of outcomes.
Association of factor VIII and factor IX mutations, HLA Class II, tumour necrosis factor-? and interleukin-10 on inhibitor development among Thai haemophilia A and B patients.
Availability of clotting factor concentrates in genetically engineered form.
Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD/SCID?c
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer.
Biological rationale for new drugs in the bleeding disorders pipeline.
Carrier detection in hemophilia using pedigree analysis coagulation tests and DNA probes.
Catalytic domain modification and viral gene delivery of activated Factor VII confers hemostasis at reduced expression levels and vector doses in vivo.
Causes of death and mortality trends related to hemophilia in Brazil, 1999 to 2016.
Cell-matrix Interactions of Factor IX (FIX)-engineered human mesenchymal stromal cells encapsulated in RGD-alginate vs. Fibrinogen-alginate microcapsules.
Changes in the Factor VIII C2 domain upon membrane binding determined by hydrogen-deuterium exchange MS.
Characteristics and thrombogenicity of factor IX concentrate.
Circulating factor IX antigen-inhibitor complexes in hemophilia B- following infusion of a factor IX concentrate.
Circulating immune complexes in haemophilia and von Willebrand's disease.
Classical haemophilia (AHF deficiency) and Christmas factor (PTC) deficiency as simultaneous defects.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Clinical pattern of hemophilia and causes of variability.
Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
Clot waveform of APTT has abnormal patterns in subjects with COVID-19.
Combined antihaemophilic globulin and Christmas factor deficiency in haemophilia.
Combined factor VIII and IX deficiency in a family.
Combined hereditary disorders of haemophilia B Leyden (-6 G-->A) and type 1 von Willebrand disease.
Common intragenic and extragenic polymorphisms of blood coagulation factors VIII and IX are different in Chinese and Caucasian populations.
Common themes and challenges in hemophilia care: a multinational perspective.
Comparative efficacy of nonheated and heat-treated factor IX complex concentrate in treatment of hemophiliacs with inhibitors.
Comparison of the behavior of normal factor IX and the factor IX Bm variant Hilo in the prothrombin time test using tissue factors from bovine, human, and rabbit sources.
Comprehensive care for hemophilia and other inherited bleeding disorders.
Congenital bleeding disorders of the vitamin K-dependent clotting factors.
Congenital defect of Christmas factor (P.T.C.) I. Haemophilia B in seven male patients.
Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia.
Consensus on hemophilia in Mexico.
Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia.
Considerations on activity assay discrepancies in factor VIII and factor IX products.
Continuous infusion of coagulation factors.
Contrast venography in young haemophiliacs with implantable central venous access devices.
Correlation of antibodies to LAV/HTLV III in hemophiliacs with the use of virus-inactivated clotting factors.
Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China.
Cost-Utility Analysis of Home-Based Care for Treatment of Thai Hemophilia A and B.
Coumarin-induced abnormal factor IX: an immunological study in humans.
Cranial hemophilic pseudotumor associated with factor IX deficiency: case report.
CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.
Current challenges in the management of hemophilia.
Current options and new developments in the treatment of haemophilia.
Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies.
Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
Danazol fails to increase factor VIII or IX levels in a double-blind crossover study of patients with haemophilia A and B.
Danazol increases factor VIII and factor IX in classic hemophilia and Christmas disease.
Declining trends in invasive orthopedic interventions for people with hemophilia enrolled in the Universal Data Collection program (2000-2010).
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
Design and characterization of an APC-specific serpin for the treatment of hemophilia.
Detection of carriers of haemophilia B.
Determinants of drug costs in hopitalised patients with haemophilia: impact of recombinant activated factor VII.
Development of anaphylactic shock in haemophilia B patients with inhibitors.
DIC and postoperative wound bleeding under factor IX. Substitution therapy in a case of hemophilia B; sucessful treatment with heparin.
Dolly, Polly and other 'ollys': likely impact of cloning technology on biomedical uses of livestock.
Early treatment of hemophilia with minimal doses of factor VIII or factor IX.
Effectiveness of ankle fusion in patients with hemophilia, advanced ankle degeneration, and unbearable pain for whom nonsurgical and surgical treatments have been ineffective.
Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery.
Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors.
Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
Emicizumab Prophylaxis in Hemophilia A with Inhibitors.
Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice.
Enhanced Pharmacokinetics of Factor VIIa as a Monomeric Fc Fusion.
Epidemiology of fractures in patients with haemophilia.
Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors.
European study on orthopaedic status of haemophilia patients with inhibitors.
Evaluation of CDC's Hemophilia Surveillance Program - Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States.
Evaluation of the plasma quality after filtration.
Ex Vivo Stromal Cell Electroporation of Factor IX cDNA for Treatment of Hemophilia B.
Exposure-Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII.
Expression of biologically active human factor IX in human hematopoietic cells after retroviral vector-mediated gene transduction.
Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
Factor IX alloantibodies shorten the bovine thromboplastin coagulation time of normal human plasma.
Factor IX and prothrombin in amniotic fluid and fetal plasma: constraints on prenatal diagnosis of hemophilia B and evidence of proteolysis.
Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.
Factor IX Deventer-evidence for the heterogeneity of hemophilia BM.
Factor IX gene haplotypes and its relevance for the indirect genetic analysis of haemophilia B in its Indian perspective.
Factor IX gene therapy for hemophilia.
Factor IX: Insights from knock-out and genetically engineered mice.
Factor VIII and factor IX concentrates in surgery in hemophilia.
Factor VIII and IX gene polymorphisms and carrier analysis in Indian population.
Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis.
Factors that influence the bleeding phenotype in severe hemophilic patients.
Failure of immunosuppression in a severe haemophilia B patient with specific antibody.
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias.
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
Financing the rising cost of haemophilia care at a large comprehensive care centre.
Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo.
Functions of AAV-CMV-F.IX And AAV-EF1alpha-F.IX in gene therapy for hemophilia B.
Future of coagulation factor replacement therapy.
FVIIa as used pharmacologically is not TF dependent in hemophilia B mice.
FVIIIa-mimetic bispecific antibody (Mim8) ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
Gene deletions correlate with the development of alloantibodies in von Willebrand disease.
Gene therapy for bleeding disorders.
Gene therapy for hemophilia.
Gene Therapy for Hemophilia.
Gene therapy for hemophilia.
Gene therapy for hemophilia: Current status and laboratory consequences.
Gene therapy for hemophilias: the end of phenotypic testing or the start of a new era?
Gene Therapy for Inherited Bleeding Disorders.
Gene therapy in an era of emerging treatment options for hemophilia B.
Gene Therapy in Hemophilia: Recent Advances.
Gene therapy of hemophilia.
Gene therapy of the hemophilias.
Gene transfer as an approach to treating hemophilia.
Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?
General surgery in adult hemophiliacs.
Genetic causes of haemophilia in women and girls.
Genetic diagnosis of haemophilia and other inherited bleeding disorders.
Genetic risk factors for inhibitors to factors VIII and IX.
Genetically modified adipose tissue-derived stem/stromal cells, using simian immunodeficiency virus-based lentiviral vectors, in the treatment of hemophilia B.
Genome-editing technologies for gene correction of hemophilia.
Haemophilia B carrier detection by factor IX:C analysis; no impact of the type of mutation or severity of disorder.
Haemophilia B caused by a missense mutation in the prepeptide sequence of factor IX.
Haemophilia B in a girl.
Haemophilia gene therapy: Progress and challenges.
Haemophilia: factoring in new therapies.
Haemorrhage in upper cervical cord: an unusual manifestation in moderate haemophilia patients who ride motorbikes.
Haemostatic efficacy of single-dose factor administration in neonates with severe haemophilia undergoing circumcision.
Haplotype analysis of identical factor IX mutants using PCR.
Hemophilia a and hemophilia B: different types of diseases?
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
Hemophilia BM in a female.
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.
Hemophilia Gene Therapy: Ready for Prime Time?
Hemophilia therapy: the future has begun.
Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Heteroduplex analysis in hemophilia B: detection of two novel factor IX gene mutations.
Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
How I treat children with haemophilia and inhibitors.
Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors.
Human factor VIII can be packaged and functionally expressed in an adeno-associated virus background: applicability to haemophilia A gene therapy.
Human T-lymphotropic retrovirus type III/lymphadenopathy-associated virus antibody. Association with hemophiliacs' immune status and blood component usage.
Hyperactive Factor IX Padua: A Game-Changer for Hemophilia Gene Therapy.
Identification of patients with congenital hemophilia in a large electronic health record database.
Immune implications of gene therapy for hemophilia.
Immunologic aberrations, HIV seropositivity and seroconversion rates in patients with hemophilia B.
Immunologic status of hemophilia patients treated with cryoprecipitate or lyophilized concentrate.
Immunologic survey of the factor IX molecule in hemophilia B+ patients, carriers and cord blood.
Immunological heterogeneity of haemophilia B: a multicentre study of 98 kindreds.
Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature review.
Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.
Implantable venous access devices in children with hemophilia: a report of low infection rates.
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
Importance of pharmacokinetics in the management of hemophilia.
In vivo bypass of hemophilia A coagulation defect by factor XIIa implant.
Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Incidence, significance, and subtypes of hemophilia BM in a large population of hemophilia B patients.
Induced human pluripotent stem cells and advanced therapies Future perspectives for the treatment of haemophilia?
Inhibitor antibodies to factor VIII and factor IX: management.
Inhibitors in congenital coagulation disorders.
Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients.
Inhibitors in haemophilia: what have we learned from registries? A systematic review.
Inhibitors in Patients with Congenital Bleeding Disorders Other Than Hemophilia.
Inhibitors in young boys with haemophilia.
Is haemophilia B less severe than haemophilia A?
Is the detection of factor IX inhibitors in hemophilia B orphan than factor VIII inhibitors in hemophilia A? A concise, systematic review.
Knee arthroplasty in hemophilic arthropathy.
Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.
Laboratory testing in hemophilia: impact of factor and non-factor replacement therapy on coagulation assays.
Lack of immune response to mouse IgG in previously untreated haemophilia A and haemophilia B patients treated with monoclonal antibody purified factor VIII and factor IX preparations.
Lasting power of new clotting proteins.
Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
Low Dose Prophylaxis vis-a-vis on-Demand Treatment Strategies for Hemophilia: A Cost Effective and Disability Attenuating Approach.
Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.
Macrohematuria as initial presentation in a girl with factor VIII and factor IX inhibitors associated with systemic lupus erythematosus.
Management of joint bleeding in hemophilia.
Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas.
Mechanisms of Bone Remodeling Disorder in Hemophilia.
Microfluidic hemophilia models using blood from healthy donors.
Milestones in hemophilia and concepts in future clinical trial design.
MiR-128 and miR-125 regulate expression of coagulation Factor IX gene with nonsense mutation by repressing nonsense-mediated mRNA decay.
Mitigation of T-cell dependent immunogenicity by reengineering factor VIIa analogue.
Modifiers of clinical phenotype in severe congenital hemophilia.
Molecular Analysis of Factor VIII and Factor IX Genes in Hemophilia Patients: Identification of Novel Mutations and Molecular Dynamics Studies.
Molecular defect in factor IX Tokyo: substitution of valine-182 by alanine at position P2' in the second cleavage site by factor XIa resulting in impaired activation.
Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptide.
Molecular evidence of HIV-1 transmission in 20 Korean individuals with haemophilia: phylogenetic analysis of the vif gene.
Mutation rates in humans. II. Sporadic mutation-specific rates and rate of detrimental human mutations inferred from hemophilia B.
Mutational Profiles of F8 and F9 in a Cohort of Haemophilia A and Haemophilia B Patients in the Multi-ethnic Malaysian Population.
Mutations in hemophilia Bm occur at the Arg180-Val activation site or in the catalytic domain of factor IX.
Mutations in the catalytic domain of factor IX that are related to the subclass hemophilia Bm.
Myocardial infarction after factor IX therapy.
New assays for monitoring haemophilia treatment.
New high-technology products for the treatment of haemophilia.
Next Generation Antibody Therapeutics Using Bispecific Antibody Technology.
No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
Non-Compartment and compartmental pharmacokinetics, efficacy, and safety of Kedrion FIX concentrate.
Non-factor replacement therapy for haemophilia: a current update.
Nonviral gene therapy approaches to hemophilia.
Novel assays in the coagulation laboratory: a clinical and laboratory perspective.
Novel missense mutation in the coagulation factor IX catalytic domain associated with severe haemophilia B--Factor IXDelhi.
Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.
Novel therapeutics for hemophilia and other bleeding disorders.
Obstacles and future of gene therapy for hemophilia.
Onco-retroviral and lentiviral vector-based gene therapy for hemophilia: preclinical studies.
Operative management of hemophilic arthropathy-an overview.
Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
Orthopaedic and surgical features in the management of patients with haemophilia.
Orthopedic Problems about the Ankle in Hemophilia.
Orthopedic surgery in hemophilic patients with musculoskeletal disorders: A systematic review.
Orthopedic surgery is possible in hemophilic patients with inhibitors.
Outcomes in total elbow arthroplasty in patients with haemophilia at the University of California, San Francisco: a retrospective review.
Over two decades of orthopaedic surgery in patients with inhibitors-Quantifying the complication of bleeding.
PEGylated therapeutic proteins for haemophilia treatment: a review for haemophilia caregivers.
Pelvic haemophilic pseudotumour occurring in a patient with mild haemophilia: a brief report.
Pelvic haemophilic pseudotumour: management of a patient with high level of inhibitors.
Pennsylvania state-wide hemophilia program: summary of immediate reactions with the use of factor VIII and factor IX concentrate.
Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules.
Pharmaceutical Approval Update.
Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.
Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B.
Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors.
Physical activity in individuals with haemophilia and experience with recombinant factor VIII Fc fusion protein and recombinant factor IX Fc fusion protein for the treatment of active patients: a literature review and case reports.
Plasma-derived biological medicines used to promote haemostasis.
Polymorphisms associated with the FVIII and FIX genes in the Turkish population.
Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources.
Potential for cellular stress response to hepatic factor VIII expression from AAV vector.
Potential role of recombinant factor VIIa as a hemostatic agent.
Potentially catastrophic bleeding disorders. Approach to diagnosis and management.
Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical Perspective.
Preclinical gene therapy studies for hemophilia using adenoviral vectors.
Preliminary study on non-viral transfection of F9 (factor IX) gene by nucleofection in human adipose-derived mesenchymal stem cells.
Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey.
Prevention and control of haemophilia: memorandum from a joint WHO/WFH meeting (World Federation of Haemophilia)
Prevention and Management of Bleeding Episodes in Children with Hemophilia.
Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
Problems and solutions in laboratory testing for hemophilia.
Prolonged Activated Partial Thromboplastin Time: Difficulties in Discriminating Coexistent Factor VIII Inhibitor and Lupus Anticoagulant.
Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.
Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.
Prospective audit of patients with haemophilia: Bleeding episodes and management.
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.
Proteolytic antibodies activate factor IX in patients with acquired hemophilia.
Pseudotumor of the Mandible as First Presentation of Hemophilia in a 2-Year-Old Male: A Case Report and Review of Jaw Pseudotumors of Hemophilia.
Rabbit polyclonal antibodies against the calcium-dependent conformation of factor IX and their application in solid phase immunoradiometric assays.
Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
Real-World Early Treatment with Room Temperature-Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses.
Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
Recent progress in gene therapy for hemophilia.
Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage.
Recombinant coagulation factor VIIa: from the concept to clinical application in hemophilia treatment in 2000.
Recombinant factor IX secreted by transduced human keratinocytes is biologically active.
Recombinant factor IX.
Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors.
Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting.
Recombinant factor VIII in hemophilia A: the Canadian experience.
Recombinant FIX Fc fusion protein activity assessment with the one-stage clotting assay: A multicenter, assessor-blinded, prospective study in Japan (J-Field Study).
Recurrent mutations in the factor IX gene: founder effect or repeat de novo events. Investigation of the German haemophilia B population and review of de novo mutations.
Replacing bad (F)actors: hemophilia.
Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
Risk factors associated with invasive orthopaedic interventions in males with haemophilia enrolled in the Universal Data Collection program from 2000 to 2010.
Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses.
Rituximab for adolescents with haemophilia and high titre inhibitors.
Rituximab for treating inhibitors in people with inherited severe hemophilia.
Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
Safety and efficacy of high-purity concentrates in haemophiliac patients undergoing surgery by continuous infusion.
Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A.
Sensitivity of the reaction time of the resonance thrombogram for factor VIII:C and factor IX deficiencies in the blood of dogs with haemophilia A or B.
Severe factor VIII and factor IX deficiency in females.
Severe hemophilia and physiologic inhibitors of coagulation.
Sine-wave Current for Efficient and Safe In Vivo Gene Transfer.
Special lectures in haemophilia management.
Spectrum of hereditary coagulation factor deficiencies in eastern province, Saudi Arabia.
Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres.
Strategies for individualized dosing of clotting factor concentrates and desmopressin in hemophilia A and B.
Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.
Studies of factor IX concentrate therapy in hemophilia.
Successful intraosseous factor VIII application in a haemophilic emergency.
Successful percutaneous coronary intervention for acute coronary syndrome in a patient with haemophilia B.
Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor.
Successful treatment of massive acute lower gastrointestinal bleeding in diverticular disease of colon, with activated recombinant factor VII (NovoSeven).
Supplying Clotting Factors From Hematopoietic Stem Cell-derived Erythroid and Megakaryocytic Lineage Cells.
Surgical excision of hemophilic pseudotumor of the ilium.
Surgical Risk on Patients with Coagulopathies: Guidelines on Hemophiliac Patients for Oro-Maxillofacial Surgery.
Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis.
Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.
Targeting Protease Nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.
Targeting TFPI for hemophilia treatment.
Targeting Translation Termination Machinery with Antisense Oligonucleotides for Diseases Caused by Nonsense Mutations.
The abnormal factor IX of hemophilia B+ variants.
The diagnosis and management of congenital hemophilia.
The evolution of recombinant factor replacement for hemophilia.
The history of hemophilia.
The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.
The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
The molecular genetics of hemophilia A and B in man. Factor VIII and factor IX deficiency.
The natural history of mild haemophilia: a 30-year single centre experience.
The odds and implications of coinheritance of hemophilia A and B.
The Patient Experience of Gene Therapy for Hemophilia: Qualitative Interviews with Trial Patients.
The Pennsylvania hemophilia program 1973-1978.
The pharmacokinetics of factor VIII and factor IX: methodology, pitfalls and applications.
The prevalence and risk factors of inhibitor development of FVIII in previously treated patients with hemophilia A.
The prevalence of AIDS-associated oral lesions in a cohort of patients with hemophilia.
The safety of pharmacologic options for the treatment of persons with hemophilia.
The spectrum of human immunodeficiency virus infection in patients with factor IX deficiency (Christmas disease)
The three in-frame ATG, clustered in the translation initiation sequence of human factor IX gene, are required for an optimal protein production.
The use of continuous infusion of factor concentrates in the treatment of hemophilia.
Therapy with factor IX concentrate resulting in DIC and thromboembolic phenomena.
Three point mutations in the factor IX genes of five hemophilia B patients. Identification strategy using localization by altered epitopes in their hemophilic proteins.
Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A.
Thrombogenicity of factor IX complex: in vivo investigation.
Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.
Tolerogenic properties of Fc portion of IgG and its relevance to the treatment and management of hemophilia.
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom.
Treatment of haemophilia: From replacement to gene therapy.
Treatment strategies in children with hemophilia.
Trends in novel treatments for hemophilia.
TT virus contaminates first-generation recombinant factor VIII concentrates.
Turnover of prothrombin, factor VII and factor IX in a patient with hemophilia A.
Viral vector-mediated gene therapy for hemophilia.
Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
What´s new in Gene Therapy of Hemophilia
Why does the mutation G17736A/Val107Val (silent) in the F9 gene cause mild haemophilia B in five Swedish families?
Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies.
Women and girls with haemophilia and bleeding tendencies: Outcomes related to menstruation, pregnancy, surgery and other bleeding episodes from a retrospective chart review.
Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States.
Zinc Finger Nucleases: Tailor-made for Gene Therapy.
[A case of hemophilia with associated deficiency of anti-hemophilic globulin and Christmas factor.]
[Articular and muscular hemorrhages in hemophilia A with anti-factor VIII antibodies. Treatment with selected batches of PPSB (factor IX concentrate)]
[Coagulation factor IX gene mutations of ten patients with hemophilia B].
[Congenital Christmas factor (CTP) defect. I. Hemophilia B in 7 males.]
[Congenital haemorrhagic diseases].
[Current status and future prospects of hemophilia treatment]
[Dental and oral surgical treatment of a B haemophilic patient with high inhibitor level. Case report].
[Development of gene therapy for hemophilia: current states and future perspectives].
[Diagnosis and management of hemophilia].
[Diagnosis and treatment of hemophilia A acquired during postpartum ].
[Effect of factor VIII, factor IX and immunoglobulin preparations on mitogen-induced lymphocyte proliferation]
[Hemophilia BM (abnormal factor IX in coagulation disorder) (author's transl)]
[Hemophilic patients. Treatment protocol in the dental office]
[Hemorrhagic congenital diseases: What can be the future of plasma-derived products against recombinants?].
[Immune coagulation disorders (excluding antiphospholipid syndrome]
[Paradoxical bleeding as a complication of the treatment of hemophilia with factor VIII and factor IX preparations]
[Perioperative management of patients with hemophilia].
[Peripartum period and hemophilia carriers].
[Plasma fractionation. Progress, problems and perspectives]
[Presence of inactive factor ix in variants of hemophilia, type B, and in carriers of hemophilia B]
[Preventive treatment of B type hemophilia: comparative evaluation between plasma and a concentrate of factor IX]
[Prophylaxis in patients with haemophilia complicated by inhibitors].
[Radical prostatectomy in a patient with hemophilia B]
[Refractory acquired hemophilia A in which factor VIII inhibitor was not detected at onset and thereafter deteriorated after total hip replacement arthroplasty]
[Structure and function of factor VIII and factor IX gene and molecular DNA diagnosis in hemophilia A and B]
[Studies on factor IX (with a contribution to the method of factor IX determination and on the etiology of hemophilia B).]
[Studies on hemophilia in Poland. II. AHG & Christmas factor deficiency with prolonged bleeding time (vascular hemophilia A & B).]
[Substitution treatment of hemophilia a and b]
[Successful management of neurosurgical procedures with continuous infusion of recombinant factor IX in a child with hemophilia B].
Hemophilia B
'DO NOT DO' RECOMMENDATIONS IN HEMOPHILIA.
A Candidate Activation Pathway for Coagulation Factor VII.
A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
A coagulation factor IX-deficient mouse model for human hemophilia B.
A codon 338 nonsense mutation in the factor IX gene in unrelated hemophilia B patients: factor IX338 New York.
A common G10430A mutation (Gly 60 Ser) in the factor IX gene describes the presence of moderate and mild hemophilia B in the majority of the Gujarati population.
A comparison of coagulation factor replacement with and without prednisolone in the treatment of haematuria in haemophilia and Christmas disease.
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
A complete deletion of the factor IX gene and new TaqI variant in a hemophilia B kindred.
A CpG Mutational Hotspot in a ONECUT Binding Site Accounts for the Prevalent Variant of Hemophilia B Leyden.
A de novo intragenic deletion of the potential EGF domain of the factor IX gene in a family with severe hemophilia B.
A de novo translocation 46,X,t(X;15) causing haemophilia B in a girl: a case report.
A deletion located in the 3' non translated part of the factor IX gene responsible for mild haemophilia B.
A deletion mutation causes hemophilia B in Lhasa Apso dogs.
A diagnostic challenge: mild hemophilia B with normal activated partial thromboplastin time.
A Dutch family with moderately severe hemophilia B (factor IXHeerde) has a missense mutation identical to that of factor IX London 2.
A factor IX gene probe: its use in carrier detection, antenatal diagnosis and characterisation of the molecular basis for hemophilia B.
A factor IX mutation, verified by direct genomic sequencing, causes haemophilia B by a novel mechanism.
A five year experience of the use of factor IX type DE(I) concentrate for the treatment of Christmas disease of Oxford.
A genetic analysis of 23 Chinese patients with hemophilia B.
A genetic variant of factor IX with decreased capacity for Ca2+ binding.
A global view on prophylaxis: possibilities and consequences.
A Gly --> Ser change causes defective folding in vitro of calcium-binding epidermal growth factor-like domains from factor IX and fibrillin-1.
A haemophilia B patient with severe burn injury: increased requirement for factor IX replacement therapy associated with venous thromboembolism.
A Highly Productive CHO Cell Line Secreting Human Blood Clotting Factor IX.
A Line 1 insertion in the Factor IX gene segregates with mild hemophilia B in dogs.
A method of assaying Christmas factor; its application to the study of Christmas disease (factor-ix deficiency).
A method to estimate effects of amino acid substitutions in blood coagulation factor IX from hemophilia B patients.
A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice.
A mutation in the 3' untranslated region of the factor IX gene in four families with hemophilia B.
A national French noninterventional study to assess the long-term safety and efficacy of reformulated nonacog alfa.
A new case of severe hemophilia B Leyden, associated with a G to C mutation at position -6 of the factor IX promoter.
A new drug form of blood coagulation factor IX: red blood cell-entrapped factor IX.
A new era for hemophilia B treatment.
A new in silico approach to investigate molecular aspects of factor IX missense causative mutations and their impact on the hemophilia B severity.
A new treatment strategy for hemophilia B: incorporation of factor IX into red cell ghosts.
A novel gene expression system: non-viral gene transfer for hemophilia as model systems.
A novel haemophilia B defect due to partial duplication of the factor IX gene.
A novel mutation (Val-373 to Glu) in the catalytic domain of factor IX, resulting in moderately/severe hemophilia B in a southern French patient.
A novel nonsense mutation in exon 2 of the factor IX gene resulting in severe haemophilia B.
A past mutation at isoleucine 397 is now a common cause of moderate/mild haemophilia B.
A pelvic pseudotumor in a nonhemophilic patient: an unusual presentation.
A Pre-conditioning Strategy to Augment Retention and Engraftment Rate of Donor Cells during Hepatocyte Transplantation.
A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
A prospective surveillance study in haemophilia B patients following a population switch to recombinant factor IX (nonacog gamma).
A quantitative two-stage assay for factor IX (Christmas factor) using plasma from dogs with Christmas disease.
A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.
A simple assay for human factor IX: use of canine hemophilia B plasma as substrate.
A simple method for analyzing factor IX activation in the patients with hemophilia B variants.
A simple technique to reduce epistaxis and nasopharyngeal trauma during nasotracheal intubation in a child with factor IX deficiency having dental restoration.
A single base pair deletion in the promoter region of the factor IX gene is associated with haemophilia B.
A single centre retrospective study of low dose prophylaxis with extended half-life factor IX for severe haemophilia B.
A study of cell mediated and humoral immunity in haemophilia and related disorders.
A study of gene transfer and expression of human clotting factor IX in hemophilia B mice mediated by mini-adenoviral vector.
A test method for the absence of thrombogenicity in factor IX complex.
A-793 G to A transition in the factor IX gene promoter is polymorphic in the Caucasian population.
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.
AAV-mediated gene transfer for hemophilia.
AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects.
Abciximab for the treatment of an acute thrombotic coronary occlusion during stent implantation in a patient with severe hemophilia B.
Abnormal B-cell function in hemophiliacs treated with cryoprecipitate and factor VIII and IX concentrates.
Abnormal bleeding phenotype for mild haemophilia B patients with the p.Ile112Thr variation on the gene for factor IX.
Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony.
Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
Abstracts.
Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction.
Acquired dysfibrinogenemia in a hemophiliac with hepatoma: resolution of fibrinogen dysfunction following chemotherapy.
Acquired factor IX deficiency in the nephrotic syndrome.
Acquired factor IX deficiency. A report of two cases.
Acquired factor IX inhibitor in a patient with Christmas disease: case report.
Acquired haemophilia A: errors in the diagnosis.
Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.
Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.
Activation of normal and abnormal human factor IX with trypsin.
Active gamma-carboxylated human factor IX expressed using recombinant DNA techniques.
Acute effects with reference to thrombogenicity and liver toxicity after injection of different coagulation factor concentrates.
Acute hepatitis in a patient with mild factor IX deficiency after anesthesia with isoflurane.
Acute myelogenous leukemia in a patient with severe factor IX deficiency.
Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy.
Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice.
Adult lifetime cost of hemophilia B management in the US: payer and societal perspectives from a decision analytic model.
Age-related factor IX correction in symptomatic female carriers with haemophilia B Leyden.
AIDS and haemophilia.
Allelic heterogeneity of molecular events in human coagulation factor IX in Asian Indians. Mutation in brief #965. Online.
Alloantibodies in hemophilia B binding to multiple factor IX epitopes.
Alloantibodies to factor IX in Haemophilia B characterized by crossed immunoelectrophoresis and enzyme-conjugated antisera to human immunoglobulins.
Alprolix (recombinant Factor IX Fc fusion protein): extended half-life product for the prophylaxis and treatment of hemophilia B.
Amelioration of clinical severity of similar mutations severe factor IX deficiency by coinherited thrombophilia.
Amino acids responsible for reduced affinities of vitamin K-dependent propeptides for the carboxylase.
Aminoglycoside suppression of nonsense mutations in severe hemophilia.
An A to T transversion at position -5 of the factor IX promoter results in hemophilia B.
An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa.
An HhaI polymorphism is present in factor IX genes of Asian subjects.
An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8(+) T Cells.
An immunologic evaluation of hemophiliac patients and their wives. Relationships to the acquired immunodeficiency syndrome.
An immunological investigation of hemophilia B with a tentative classification of the disease into five variants.
An immunological method for detection of the carrier of hemophilia B.
An important role for the activation peptide domain in controlling factor IX levels in the blood of haemophilia B mice.
An insertion within the factor IX gene: hemophilia BEl Salvador.
An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B.
An intragenic deletion of the factor IX gene in a family with hemophilia B.
An investigation of three patients with Christmas disease due to an abnormal type of factor IX.
An MseI RFLP in the 5' flanking region of the factor IX gene: its use for haemophilia B carrier detection in Caucasian and Thai populations.
An open clinical study assessing the efficacy and safety of Factor IX Grifols((R)), a high-purity Factor IX concentrate, in patients with severe haemophilia B.
An unusual case of pleural-based tumor with life-threatening post-operative complication.
An unusual complication in a gravida with factor IX deficiency: case report with review of the literature.
An Unusual Presentation of Hemophilia A: Pseudotumor of Distal End Radius-Masquerading as Giant Cell Tumor.
Analysis of F9 point mutations and their correlation to severity of haemophilia B disease.
Analysis of haemophilia B database and strategies for identification of common point mutations in the factor IX gene.
Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
Anaphylactoid reactions and nephrotic syndrome--a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers.
Anaphylaxis Following Human Prothrombin Complex Concentrate in a Child with Lupus Anticoagulant Hypoprothrombinemia Syndrome: A Cautionary Tale.
Anasarca improved by extracorporeal ultrafiltration through an internal shunt in a case of severe haemophilia B with inhibitor and steroid-resistant nephrotic syndrome.
Androgen effects on factor IX expression: in-vitro and in-vivo studies in mice.
Anion-exchange purification of recombinant factor IX from cell culture supernatant using different chromatography supports.
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
Aortic and mitral valve replacement in a patient with hemophilia B.
Aplastic anemia in a patient with factor IX deficiency.
Apparent synonymous mutation F9 c.87A>G causes secretion failure by in-frame mutation with aberrant splicing.
Arthroscopic synovectomy of the knee in hemophilia: 10-to-15 year followup.
Assessing bleeding rates, related clinical impact and factor utilization in German hemophilia B patients treated with extended half-life rIX-FP compared to prior drug therapy.
Assessing the underlying pattern of human germline mutations: lessons from the factor IX gene.
Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies.
Autologous and Heterologous Cell Therapy for Hemophilia B toward Functional Restoration of Factor IX.
Bacterial endocarditis in a child with haemophilia B: risks of central venous catheters.
Balloon Catheter Delivery of Helper-dependent Adenoviral Vector Results in Sustained, Therapeutic hFIX Expression in Rhesus Macaques.
Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.
BAX326 (RIXUBIS): a novel recombinant factor IX for the control and prevention of bleeding episodes in adults and children with hemophilia B.
Bilateral hemorrhagic proptosis due to an uncommon cause in ocular emergency.
Bilateral subthalmic nucleus deep brain stimulation with microelectrode recordings in the setting of mild inherited Hemophilia B: A case report.
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer.
Binding of the Ets factor GA-binding protein to an upstream site in the factor IX promoter is a critical event in transactivation.
Biodegradable hydrophilic carriers for the oral delivery of hematological factor IX for hemophilia B treatment.
Biodistribution and pharmacokinetics of transgenic pig-produced recombinant human factor IX (rhFIX) in rats.
Biodistribution of the recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in rats.
Bioengineered Factor IX Molecules with Increased Catalytic Activity Improve the Therapeutic Index of Gene Therapy Vectors for Hemophilia B.
Biology of bone marrow stroma.
Biology of factor IX.
Bleeding Disorders in Adolescents with Heavy Menstrual Bleeding: The Queensland Statewide Paediatric and Adolescent Gynaecology Service.
Blood clotting factor IX BM Nagoya. Substitution of arginine 180 by tryptophan and its activation by alpha-chymotrypsin and rat mast cell chymase.
Blood clotting factor IX Kashihara: amino acid substitution of valine-182 by phenylalanine.
Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.
Blood clotting factor IX Niigata: substitution of alanine-390 by valine in the catalytic domain.
Bone marrow stromal cells as a genetic platform for systemic delivery of therapeutic proteins in vivo: human factor IX model.
Breakpoint of a balanced translocation (X:14) (q27.1;q32.3) in a girl with severe hemophilia B maps proximal to the factor IX gene.
Calcium-binding EGF-like modules in coagulation proteinases: function of the calcium ion in module interactions.
Canine hemophilia B resulting from a point mutation with unusual consequences.
Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors.
Cardiac surgery in patients with haemophilia B: a case report and review of the literature.
Carrier detection and feasibility of prenatal diagnosis of hemophilia B by multiplex polymerase chain reaction.
Carrier detection by direct gene analysis in a family with haemophilia B (factor IX deficiency).
Carrier detection in haemophilia B using two further intragenic restriction fragment length polymorphisms.
Carrier detection of Hemophilia B by using a restriction site polymorphism associated with the coagulation Factor IX gene.
Carrier detection through the use of abnormal deletion junction fragments in a case of haemophilia B involving complete deletion of the factor IX gene.
Carrier testing and prenatal diagnosis of haemophilia B by SSCP in an Iranian family.
Carrier testing in hemophilia B with an immunoassay that distinguishes a prevalent factor IX dimorphism.
Catalytic domain modification and viral gene delivery of activated Factor VII confers hemostasis at reduced expression levels and vector doses in vivo.
CD8(+) T cell recognition of epitopes within the capsid of adeno-associated virus 8 based gene transfer vectors depends on vectors' genome.
CG dinucleotide transitions in the factor IX gene account for about half of the point mutations in hemophilia B patients: a Seattle series.
Challenges in the management of hemophilia B with inhibitor.
Change of antigenic and neutralizing specificity in substitutional epitope peptides of hemophilia B inhibitor.
Changes of coagulation factors IX, VIII, VII, X, and V in nephrotic syndrome.
Characterisation of factor IX with a glycine-to-valine missense mutation at residue 190 in a patient with severe haemophilia B.
Characterisation of the tolerant state in a patient with haemophilia B after removal of high-titre factor IX antibodies.
Characterization and experimental use of a monospecific antiserum to factor IX.
Characterization of a factor IX variant with a glycine207 to glutamic acid mutation.
Characterization of an occult inhibitor to factor IX in a haemophilia B patient.
Characterization of factor IX defects in hemophilia B patients.
Characterization of genetic defects of hemophilia B of Chinese origin.
Characterization of heterogeneity of haemophilia B for the detection of carriers.
Characterization of missense mutations in the signal peptide and propeptide of FIX in hemophilia B by a cell-based assay.
Characterization of the clotting activities of structurally different forms of activated factor IX. Enzymatic properties of normal human factor IXa alpha, factor IXa beta, and activated factor IX Chapel Hill.
Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.
Characterization of the mutations causing hemophilia B in 2 domestic cats.
Christmas disease (clotting factor IX deficiency) and the presentation of a carcinoid tumour in an inguinal hernia.
Christmas disease (haemophilia B) in a girl with deletion of the short arm of one X-chromosome (functional Turner syndrome).
Christmas disease in a Hovawart family resembling human hemophilia B Leyden is caused by a single nucleotide deletion in a highly conserved transcription factor binding site of the F9 gene promoter.
Christmas disease: diagnosis and management of a haemorrhagic diathesis following dentofacial trauma.
Chronic liver dysfunction in multitransfused hemophiliacs.
Circulating human factor IX produced in keratin-promoter transgenic mice: a feasibility study for gene therapy of haemophilia B.
Circulating immune complexes in haemophilia and von Willebrand's disease.
Clinical and laboratory features of 178 children with recurrent epistaxis.
Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine(®) in previously treated patients with severe haemophilia B.
Clinical evaluation of recombinant factor IX.
Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
Clinical experience with a highly purified factor IX concentrate in patients undergoing surgical operations.
Clinical gene transfer studies for hemophilia B.
Clinical manifestations and management of labor and delivery in women with factor IX deficiency.
Clinical significance of two mutations in the factor IX gene in a family with haemophilia B.
Clinical utility and patient perspectives on the use of extended half-life rFIXFc in the management of hemophilia B.
Clinical, humanistic, and economic burden of severe hemophilia B in the United States: Results from the CHESS US and CHESS US+ population surveys.
Close linkage of fragile X-mental retardation syndrome to haemophilia B and transmission through a normal male.
Clot waveform of APTT has abnormal patterns in subjects with COVID-19.
Clotting factor IX levels in C/EBP alpha knockout mice.
Coagulation abnormalities in patients with Gaucher's disease: effect of therapy.
Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion(®)): A Review of Its Use in Haemophilia B.
Coagulation Factor IX for Hemophilia B Therapy.
Coagulation factor IX in normal and haemophilia B plasma.
Coagulation factor IX: successful surgical experience with a purified factor IX concentrate.
Coagulopathy in nephrotic syndrome at the time of renal biopsy.
Combined coagulation factor VIII and factor IX deficiency (CDF8F9) in a patient from Lithuania.
Combined factor IX and protein C deficiency in a child: thrombogenic effects of two factor IX concentrates.
Combined hereditary disorders of haemophilia B Leyden (-6 G-->A) and type 1 von Willebrand disease.
Comparison of four commercially available activated partial thromboplastin time reagents using a semi-automated coagulometer.
Comparison of the sensitivity of commercial APTT reagents in the detection of mild coagulopathies.
Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high-expressing human factor IX plasmid.
Complete deletion of factor IX gene and inhibition of factor IX activity in a labrador retriever with hemophilia B.
Complexity of immune responses to AAV transgene products - Example of factor IX.
Comprehensive analysis of phenotypes and genetics in 21 Chinese families with haemophilia B: characterization of five novel mutations.
Comprehensive care for hemophilia and other inherited bleeding disorders.
Computationally designed liver-specific transcriptional cis-regulatory modules and hyper-functional factor IX improve liver-targeted gene therapy for hemophilia B.
Concomitant treatment with factor IX concentrates and antifibrinolytics in hemophilia B.
Concurrent lymphoma and hemophilia B in a pediatric patient: A case report.
Conformational comparability of factor IX-Fc fusion protein, factor IX, and purified Fc fragment in the absence and presence of calcium.
Congenital bleeding disorders. Rational treatment options.
Congenital defect of Christmas factor (P.T.C.) I. Haemophilia B in seven male patients.
Consequences of factor IX mutations in 26 families with haemophilia B.
Considerations governing factor IX product choice in hemophilia B.
Construction and high expression of retroviral vector with human clotting factor IX cDNA in vitro.
Construction of human factor IX expression vectors in retroviral vector frames optimized for muscle cells.
Continuous infusion of factor concentrates: review of use in hemophilia A and demonstration of safety and efficacy in hemophilia B.
Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B.
Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.
Contrast venography in young haemophiliacs with implantable central venous access devices.
Coronary angiography with or without percutaneous coronary intervention in patients with hemophilia-Systematic review.
Coronary artery bypass grafting in a patient with haemophilia B.
Coronary artery bypass grafting in a patient with hemophilia B: continuous recombinant factor IX infusion as per the Japanese guidelines for replacement therapy.
Coronary bypass in a patient with hemophilia B, or Christmas disease. Case report.
Correction of factor IX deficiency in mice by embryonic stem cells differentiated in vitro.
Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors.
Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China.
Cranial hemophilic pseudotumor associated with factor IX deficiency: case report.
Creation of a mouse expressing defective human factor IX.
CRISPR-Cas9-Mediated In Vivo Gene Integration at the Albumin Locus Recovers Hemostasis in Neonatal and Adult Hemophilia B Mice.
CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
CRISPR/Cas9-mediated knockin of human factor IX into swine factor IX locus effectively alleviates bleeding in hemophilia B pigs.
CRISPR/Cas9-mediated somatic and germline gene correction to restore hemostasis in hemophilia B mice.
CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.
Cryoprecipitate-removed plasma 'cryo-removed plasma' as a source of factor IX in the treatment of haemophilia B.
Current challenges in the management of hemophilia.
Current management of hemophilia B: recommendations, complications and emerging issues.
Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies.
Current status of haemophilia gene therapy.
Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
Cytological mapping of the human glucose-6-phosphate dehydrogenase gene distal to the fragile-X site suggests a high rate of meiotic recombination across this site.
Danazol fails to increase factor VIII or IX levels in a double-blind crossover study of patients with haemophilia A and B.
Danazol increases factor VIII and factor IX in classic hemophilia and Christmas disease.
Decreased helper/suppressor cell ratios after treatment with factor VIII and IX concentrates and fresh frozen plasma.
Defective propeptide processing and abnormal activation underlie the molecular pathology of factor IX Troed-y-Rhiw.
Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position -4.
Delayed diagnosis of congenital factor IX deficiency (Christmas disease) in a girl with Turner's Syndrome.
Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease).
Deletion of the factor IX gene as a result of translocation t(X;1) in a girl affected by haemophilia B.
Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B.
Dental extractions and the use of Christmas factor concentrate in cases of haemophilia B.
Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review.
Design of pH-Responsive Biomaterials to Enable the Oral Route of Hematological Factor IX.
Designer nuclease-mediated gene correction via homology-directed repair in an in vitro model of canine hemophilia B.
Detailed characterization of an anti-factor IX monoclonal antibody that neutralizes the prolonged ox brain prothrombin time of hemophilia B(M) by synthetic peptides.
Detection of carrier status of hemophilia B using DNA markers.
Detection of factor IX antibodies by radioimmunoassay: effect of calcium on antibody-factor IX interaction.
Detection of factor IX inhibitors by immunoradiometric assay.
Detection of known haemophilia B mutations and carrier testing by microarray.
Detection of ten new mutations by screening the gene encoding factor IX of Danish hemophilia B patients.
Determinants of coagulation activation in humans.
Determinants of plasma factor VIIa levels in humans.
Determinants of the factor IX mutational spectrum in haemophilia B: an analysis of missense mutations using a multi-domain molecular model of the activated protein.
Determination of factor IX allotypes for carrier identification in haemophilia B.
Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX gene therapy.
Development of a Clinical Candidate AAV3 Vector for Gene Therapy of Hemophilia B.
Development of a quasispecies of human immunodeficiency virus type 1 in vivo.
Development of an In Vitro Biopotency Assay for an AAV8 Hemophilia B Gene Therapy Vector Suitable for Clinical Product Release.
Development of anaphylactic shock in haemophilia B patients with inhibitors.
Development of Methods for the Selective Measurement of the Single Amino Acid Exchange Variant Coagulation Factor IX Padua.
Development of novel treatment options for patients with haemophilia.
Developments in the treatment of hemophilia B: focus on emerging gene therapy.
Diagnosis of haemophilia B using the polymerase chain reaction.
Diagnosis of hemophilia B carriers using two novel dinucleotide polymorphisms and Hha I RFLP of the factor IX gene in Japanese subjects.
Diagnosis of two related carriers of severe haemophilia B with no family history.
Diagnostic role of an immunoassay-detected polymorphism of factor IX for potential carriers of hemophilia B.
DIC and postoperative wound bleeding under factor IX. Substitution therapy in a case of hemophilia B; sucessful treatment with heparin.
Different Types of Cell Cycle- and Apoptosis-Related Gene Expressions Alter in Corticosteroid-, Vincristine-, and Melphalan-Resistant U-266 Multiple Myeloma Cell Lines.
Differential termination of primer extension: a novel, quantifiable method for detection of point mutations.
Direct carrier detection in hemophilia B kindreds: use of modified primers (mutagenic primers) for enzymatic amplification of the factor IX gene.
Direct carrier testing of haemophilia B by SSCP.
Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications.
Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
Direct mutation analysis as the preferred method for carrier diagnosis in families with isolated cases of haemophilia B.
Disappearance of inhibitor to factor IX in a patient with severe haemophilia B and immunological characterization of the inhibitor.
Discordance in a pair of identical twin carriers of factor IX deficiency.
Discovery of An Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B.
Discrepancies between the one-stage clotting assay and the chromogenic assay in haemophilia B.
Disentangling the perturbational effects of amino acid substitutions in the DNA-binding domain of p53.
Disruption of a binding site for hepatocyte nuclear factor 4 results in hemophilia B Leyden.
Disruption of a C/EBP binding site in the factor IX promoter is associated with haemophilia B.
Disseminated intravascular coagulation and hemorrhage in hemophilia B following elective surgery.
Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy.
Distinct X chromosomal rearrangements in four haemophilia B patients with entire F9 deletion.
DNA sequence analysis of three inhibitor-positive hemophilia B patients without gross gene deletion: identification of four novel mutations in factor IX gene.
Do patients with haemophilia undergoing cardiac surgery have good surgical outcomes?
Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.
Early elevation of factor IX level in japanese brothers with Haemophilia B Leyden who are carrying c. -35 g > a mutations in the promoter region of F9.
Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy.
Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.
Effects of genetic fusion of factor IX to albumin on in vivo clearance in mice and rabbits.
Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures.
Efficacy and safety of OCTANINE F in children with haemophilia B.
Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery.
Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials.
Efficient detection of factor IX mutations by denaturing high-performance liquid chromatography in Taiwanese hemophilia B patients, and the identification of two novel mutations.
Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes.
Electroimmunoassay of factor IX in hemophilia B.
Emerging drugs for hemophilia B.
Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial.
Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice.
Endoscopic-mediated, biliary hydrodynamic injection mediating clinically relevant levels of gene delivery in pig liver.
Engineering liver tissues under the kidney capsule site provides therapeutic effects to hemophilia B mice.
Engineering protein processing of the mammary gland to produce abundant hemophilia B therapy in milk.
Enhanced Factor IX Activity following Administration of AAV5-R338L "Padua" Factor IX versus AAV5 WT Human Factor IX in NHPs.
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.
Enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to factor IX in hemophilia B.
Epitope mapping of human factor IX inhibitor antibodies.
EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.
Eradication of factor IX neutralizing and anaphylactic inhibitors in a patient with severe haemophilia B using cyclophosphamide immune suppression and factor IX desensitization.
Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice.
Evaluation of a new concentrate for the treatment of factor IX deficiency.
Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance. Results from the College of American Pathologists Survey Program.
Evaluation of CDC's Hemophilia Surveillance Program - Universal Data Collection (1998-2011) and Community Counts (2011-2019), United States.
Evaluation of CNBr, FMP and hydrazide resins for immunoaffinity purification of factor IX.
Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.
Evaluation of Nonacog Beta Pegol Long-term Safety in the Immune-deficient Rowett Nude Rat (Crl:NIH-Foxn1rnu ).
Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B.
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector.
Evidence of a predisposing locus to bipolar disorder on Xq24-q27.1 in an extended Finnish pedigree.
Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B.
Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants.
Ex Vivo Stromal Cell Electroporation of Factor IX cDNA for Treatment of Hemophilia B.
Experience with the hemophiliac child in a pediatric emergency department.
Experimental and theoretical evidence supporting the role of Gly363 in blood coagulation factor IXa (Gly193 in chymotrypsin) for proper activation of the proenzyme.
Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa.
Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients.
Expression of active human blood clotting factor IX in transgenic mice: use of a cDNA with complete mRNA sequence.
Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells.
Expression of coagulation factor IX in a haematopoietic cell line.
Expression of human factor IX by microencapsulated recombinant fibroblasts.
Expression of human factor IX cDNA in mice by implants of genetically modified skin fibroblasts from a hemophilia B patient.
Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: potential for gene therapy of hemophilia B.
Expression of human factor IX in rat capillary endothelial cells: toward somatic gene therapy for hemophilia B.
Extended half-life rFIX in major surgery-How to improve clinical practice: An intraindividual comparison.
Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B.
Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin.
Extracellular proteases and their inhibitors in genetic diseases of the central nervous system.
Extragenic factor IX gene RFLP is useful for detecting carriers of Japanese hemophilia B.
Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.
Ezetimibe: A biomarker for efficacy of liver directed UGT1A1 gene therapy for inherited hyperbilirubinemia.
Factor IX activity and factor IX antigen in haemophilia B carriers.
Factor IX and prothrombin in amniotic fluid and fetal plasma: constraints on prenatal diagnosis of hemophilia B and evidence of proteolysis.
Factor IX and thrombosis.
Factor IX antigen by a rapid staphylococcal protein A-membrane binding radioimmunoassay: results in haemophilia B patients and carriers and in fetal samples.
Factor IX antigen by radioimmunoassay in heterozygotes for hemophilia B.
Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.
Factor IX assays in treated hemophilia B patients.
Factor IX Cardiff: a variant factor IX protein that shows abnormal activation is caused by an arginine to cysteine substitution at position 145.
Factor IX Chongqing: a new mutation in the calcium-binding domain of factor IX resulting in severe hemophilia B.
Factor IX concentrate versus prothrombin complex concentrate for the treatment of hemophilia B during surgery.
Factor IX deficiency (Christmas disease).
Factor IX deficiency (haemophilia B, Christmas disease) in a crossbred dog.
Factor IX deficiency (hemophilia B) in a family of British shorthair cats.
Factor IX deficiency (hemophilia B) in a litter of Labrador retrievers.
Factor IX deficiency (hemophilia B) in a Scottish terrier.
Factor IX deficiency and anaphylaxis.
Factor IX deficiency and bleeding in a patient with Sheehan's syndrome.
Factor IX deficiency and frugal method of analysis.
Factor IX deficiency and prolonged bleeding time.
Factor IX deficiency in an Alaskan Malamute.
Factor IX deficiency in Gaucher disease. An in vitro phenomenon.
Factor IX deficiency in liver disease.
Factor IX deficiency in nephrosis.
Factor IX deficiency in the nephrotic syndrome.
Factor IX deficiency in the nephrotic syndrome: studies with prothrombin complex concentrate.
Factor IX Denver, ASN 346-->ASP mutation resulting in a dysfunctional protein with defective factor VIIIa interaction.
Factor IX Deventer-evidence for the heterogeneity of hemophilia BM.
Factor IX ectopically expressed in platelets can be stored in {alpha}-granules and corrects the phenotype of hemophilia B mice.
Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer.
Factor IX Fukuoka. Substitution of ASN92 by His in the second epidermal growth factor-like domain results in defective interaction with factors VIIa/X.
Factor IX gene analysis in 70 unrelated patients with haemophilia B: description of 13 new mutations.
Factor IX gene haplotypes and its relevance for the indirect genetic analysis of haemophilia B in its Indian perspective.
Factor IX gene haplotypes in Brazilian blacks and characterization of unusual DdeI alleles.
Factor IX gene mutations causing haemophilia B: comparison of SSC screening versus systematic DNA sequencing and diagnostic applications.
Factor IX gene mutations in haemophilia B: a New Zealand population-based study.
Factor IX gene polymorphisms in Indian population.
Factor IX gene sequencing by a simple and sensitive 15-hour procedure for haemophilia B diagnosis: identification of two novel mutations.
Factor IX gene therapy for hemophilia.
Factor IX inhibition and epitope localization of factor IX inhibitor antibodies in haemophilia B patients with anaphylactoid reactions.
Factor IX inhibitors and anaphylaxis in haemophilia B.
Factor IX inhibitors and anaphylaxis in hemophilia B.
Factor IX inhibitors: Clinical and laboratory profiles of two patients with severe haemophilia B.
Factor IX Kawachinagano: impaired function of the Gla-domain caused by attached propeptide region due to substitution of arginine by glutamine at position -4.
Factor IX levels during pregnancy in a women with hemophilia B.
Factor IX levels in patients with hemophilia B (Christmas disease) following transfusion with concentrates of factor IX or fresh frozen plasma (FFP).
Factor IX molecular defects in diagnosing hemophilia B: a review.
Factor IX mutations in haemophilia B patients in Malaysia: a preliminary study.
Factor IX mutations in hemophilia B patients from Liaoning Province, China.
Factor IX mutations: rapid, direct screening methods for 20 new families with hemophilia B.
Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B.
Factor IX of the blood coagulation system: a review.
Factor IX replacement in surgery and prophylaxis.
Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010.
Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.
Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
Factor IX variants improve gene therapy efficacy for hemophilia B.
Factor IX variants of hemophilia B. The effect of activated factor XI and the reaction product of factor VII and tissue factor on the abnormal factor IX molecules.
Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high molecular weight.
Factor IX Zutphen: a Cys18-->Arg mutation results in formation of a heterodimer with alpha 1-microglobulin and the inability to form a calcium-induced conformation.
Factor IX: Insights from knock-out and genetically engineered mice.
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Factor IXAlabama: a point mutation in a clotting protein results in hemophilia B.
Factor IXMadrid 2: a deletion/insertion in factor IX gene which abolishes the sequence of the donor junction at the exon IV-intron d splice site.
Factor VIII and IX gene polymorphisms and carrier analysis in Indian population.
Failure of immunosuppression in a severe haemophilia B patient with specific antibody.
Fatal hemorrhagic diathesis associated with mild factor IX deficiency in pl/J mice.
Female factor IX deficiency due to maternally inherited X-inactivation.
Fibrin formation, fibrinopeptide A release, and platelet thrombus dimensions on subendothelium exposed to flowing native blood: greater in factor XII and XI than in factor VIII and IX deficiency.
Final results of the PUPs B-LONG study: evaluating safety and efficacy of rFIXFc in previously untreated patients with hemophilia B.
Financing the rising cost of haemophilia care at a large comprehensive care centre.
First Case of Acquired Hemophilia B in a Patient with HIV Infection: Case Report and Literature Review.
First case report of hemophilia B Leyden in Japan.
First factor IX mutations in Albanian hemophilia B patients.
First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China.
Five novel factor IX mutations in unrelated hemophilia B families.
Five novel factor IX mutations in unrelated hemophilia B patients.
Five novel point mutations: two causing haemophilia B and three causing factor X deficiency.
FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B.
Frequency of recent retrotransposition events in the human factor IX gene.
Functional analysis of the factor IX epidermal growth factor-like domain mutation Ile66Thr associated with mild hemophilia B.
Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo.
Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.
Further evidence for the importance of an androgen response element in the factor IX promoter.
Further studies on factor IX antigen in hemophilia B.
Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity.
Fusion of Factor IX to Factor XIII-B Sub-Unit Improves the Pharmacokinetic Profile of Factor IX.
G244E in the canine factor IX gene leads to severe haemophilia B in Rhodesian Ridgebacks.
Galectin 3-binding protein is a potential contaminant of recombinantly produced factor IX.
Gastrectomy in siblings with Christmas disease (hemophilia B).
Gene deletion in an Italian haemophilia B subject.
Gene deletions correlate with the development of alloantibodies in von Willebrand disease.
Gene mutations and inhibitor formation in patients with hemophilia B.
Gene therapy for bleeding disorders.
Gene Therapy for Coagulation Disorders.
Gene therapy for hemophilia B mediated by recombinant adeno-associated viral vector with hFIXR338A, a high catalytic activity mutation of human coagulation factor IX.
Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX.
Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle.
Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression.
Gene therapy for hemophilia.
Gene Therapy for Hemophilia.
Gene therapy for hereditary hematological disorders.
Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.
Gene therapy in an era of emerging treatment options for hemophilia B.
Gene therapy of the hemophilias.
Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B.
Gene therapy, an ongoing revolution.
Gene therapy. Factor IX Padua: them that have, give.
Gene therapy: a 2001 perspective.
Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients?
Generation of a novel factor IX with augmented clotting activities in vitro and in vivo.
Genetic determinants of immunogenicity to factor IX during the treatment of haemophilia B.
Genetic fusion to albumin improves the pharmacokinetic properties of factor IX.
Genetic variants of haemophilia B detected by immunoradiometric assay: implications for prenatal diagnosis.
Germ-line origins of mutation in families with hemophilia B: the sex ratio varies with the type of mutation.
Germline mosaicism resulting in the transmission of severe hemophilia B from a grandfather with a mild deficiency.
Germline mutations in Peruvian patients with hemophilia B: pattern of mutation in AmerIndians is similar to the putative endogenous germline pattern.
Germline mutations in the factor IX gene: a comparison of the pattern in Caucasians and non-Caucasians.
Glycoengineered factor IX variants with improved pharmacokinetics and subcutaneous efficacy.
GlycoPEGylated recombinant factor IX for hemophilia B in context.
Group B streptococcal polyarthritis complicating hemophilia B.
Guideline for the treatment of haemophilia in South Africa.
Haemophilia B (sixth edition): a database of point mutations and short additions and deletions.
Haemophilia B and factor IX mutations.
Haemophilia B carrier detection by factor IX:C analysis; no impact of the type of mutation or severity of disorder.
Haemophilia B caused by a missense mutation in the prepeptide sequence of factor IX.
Haemophilia B caused by a point mutation in a donor splice junction of the human factor IX gene.
Haemophilia B caused by mutation of a potential thrombin cleavage site in factor IX.
Haemophilia B due to a de novo insertion of a human-specific Alu subfamily member within the coding region of the factor IX gene.
Haemophilia B in a female caused by skewed inactivation of the normal X-chromosome.
Haemophilia B in a girl.
Haemophilia B in female twins caused by a point mutation in one factor IX gene and nonrandom inactivation patterns of the X-chromosomes.
Haemophilia B Leyden arising de novo by point mutation in the putative factor IX promoter region.
Haemophilia B Leyden in Greece.
Haemophilia B Leyden: the effect of mutations at position +13 on the liver-specific transcription of the factor IX gene.
Haemophilia B Liverpool: a new British family with mild haemophilia B associated with a -6 G to A mutation in the factor IX promoter.
Haemophilia B: Christmas disease.
Haemophilia B: current pharmacotherapy and future directions.
Haemophilia B: database of point mutations and short additions and deletions, 7th edition.
Haemophilia B: database of point mutations and short additions and deletions, fifth edition, 1994.
Haemophilia B: database of point mutations and short additions and deletions--eighth edition.
Haemophilia B: from molecular diagnosis to gene therapy.
Haemophilia B: impact on patients and economic burden of disease.
Haemophilia B: Where are we now and what does the future hold?
Haemophilia, the journey in search of a cure. 1960-2020.
Haemophilia: factoring in new therapies.
Haemorrhage and factor IX deficiency in pituitary insufficiency.
Haemorrhage in upper cervical cord: an unusual manifestation in moderate haemophilia patients who ride motorbikes.
Half-life extension through albumin fusion technologies.
Haplotype analysis of identical factor IX mutants using PCR.
Head trauma and hemophilia B: case report about a challenging hematologic emergency.
Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine(®) ) and a recombinant factor IX (BeneFIX(®) ) in patients with severe haemophilia B.
Health care resource utilization and cost burden of hemophilia B in the United States.
Health-related quality of life in paediatric haemophilia B patients treated with rIX-FP.
Heat treated New Zealand factor IX concentrate: comparison with Prothrombinex in patients with haemophilia B.
Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo.
Hematologic risk factors for stroke in Saudi children.
Hemophilia a and hemophilia B: different types of diseases?
Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
Hemophilia B (factor IXSeattle 2) due to a single nucleotide deletion in the gene for factor IX.
Hemophilia B carrier determination based on family-specific mutation detection by DNA single-strand conformation analysis.
Hemophilia B caused by five different nondeletion mutations in the protease domain of factor IX.
Hemophilia B Durham: a mutation in the first EGF-like domain of factor IX that is characterized by polymerase chain reaction.
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
Hemophilia B in a 46,XX female probably caused by non-random X inactivation.
Hemophilia B Leyden and once mysterious cis-regulatory mutations.
Hemophilia B Leyden: substitution of thymine for guanine at position -21 results in a disruption of a hepatocyte nuclear factor 4 binding site in the factor IX promoter.
Hemophilia B mutational analysis.
Hemophilia B with inhibitor: molecular analysis of the subtotal deletion of the factor IX gene.
Hemophilia B with mutations at glycine-48 of factor IX exhibited delayed activation by the factor VIIa-tissue factor complex.
Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
Hemorrhage involving the upper airway in hemophilia.
Hemorrhagic diathesis in a carrier of hemophilia B.
Hemorrhagic tonsillitis.
Hemostatic Management in an Infant With Neuroblastoma and Severe Hemophilia B With Extended Half-life Recombinant Factor IX Fusion Protein.
Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
Hepatic gene therapy for haemophilia B.
Hepatitis A transmission by factor IX concentrates.
Hepatocyte Is a Sole Cell Type Responsible for the Production of Coagulation Factor IX In Vivo.
Hepatocyte-like cells derived from mouse induced pluripotent stem cells produce functional coagulation factor IX in a hemophilia B mouse model.
Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk.
Hereditary ring sideroblastic anaemia and Christmas disease in a Swedish family.
Heteroduplex analysis in hemophilia B: detection of two novel factor IX gene mutations.
Heteroduplex screening for molecular defects in factor IX genes from haemophilia B families.
Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
Heterogeneity of the factor IX locus in nine hemophilia B inhibitor patients.
High dose factor VIIa improves clot structure and stability in a model of haemophilia B.
High efficient transfer and expression of human clotting factor IX cDNA in cultured human primary skin fibroblasts from hemophilia B patient by retroviral vectors.
High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
High-efficiency Transduction and Correction of Murine Hemophilia B Using AAV2 Vectors Devoid of Multiple Surface-exposed Tyrosines.
High-purity factor IX concentrates for treatment of hemophilia B: relative purity and thrombogenic potential.
HIV-1 infection in haemophilia.
Homologous human blood protein separation using immobilized metal affinity chromatography: protein C separation from prothrombin with application to the separation of factor IX and prothrombin.
HTLV-III infection in homosexuals and hemophiliacs in Sweden.
Human cell lines: A promising alternative for recombinant FIX production.
Human coagulation factor IX: a systematic review of its characteristics.
Human factor IX corrects the bleeding diathesis of mice with hemophilia B.
Human factor IX for the treatment of hemophilia B.
Human factor IX in animals: kinetics from isolated, radiolabelled protein and platelet destruction following crude concentrate infusions.
Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate.
Human factor IXLincoln Park: a molecular characterization.
Human germline mutation in the factor IX gene.
Human hepatoma cell line HuH-7 is an effective cellular system to produce recombinant factor IX with improved post-translational modifications.
Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice.
Human iPS Cell-based Liver-like Tissue Engineering at Extrahepatic Sites in Mice as a New Cell Therapy for Hemophilia B.
Human plasma fibrinogen measurement derived from activated partial thromboplastin time clot formation.
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
Hyaluronidase enhances recombinant adeno-associated virus (rAAV)-mediated gene transfer in the rat skeletal muscle.
Hyperactive PiggyBac Transposons for Sustained and Robust Liver-targeted Gene Therapy.
Hyperactive sleeping beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B.
Hypercalcemia associated with normal 1,25-dihydroxyvitamin D concentrations in a neonate with factor IX deficiency.
Hyperglycosylation prolongs the circulation of coagulation factor ix.
Identification and Genetic Analysis of a Factor IX Gene Intron 3 Mutation in a Hemophilia B Pedigree in China.
Identification of a single nucleotide C-to-T transition and five different deletions in patients with severe hemophilia B.
Identification of cis-regulatory sequence variations in individual genome sequences.
Identification of factor IX mutations in haemophilia B: application of polymerase chain reaction and single strand conformation analysis.
Identification of factor IX mutations in Iranian haemophilia B patients by SSCP and sequencing.
Identification of haemophilia B patients with mutations in the two calcium binding domains of factor IX: importance of a beta-OH Asp 64----Asn change.
Identification of novel glycosylation events on human serum-derived factor IX.
Identification of T-cell epitopes in clotting factor IX and lack of tolerance in inbred mice.
Identification of the molecular defect in factor IX Chapel Hill: substitution of histidine for arginine at position 145.
Identification of twenty-one new mutations in the factor IX gene by SSCP analysis.
Identification of zebrafish ortholog for human coagulation factor IX and its age-dependent expression.
IgE-mediated allergy and desensitization to factor IX in hemophilia B.
IgG subclass identification of inhibitors to factor IX in haemophilia B patients.
Immune deviation by mucosal antigen administration suppresses gene-transfer-induced inhibitor formation to factor IX.
Immune reactive factor IX in acquired factor IX deficiency.
Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice.
Immune responses to AAV in clinical trials.
Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4.
Immune tolerance in haemophilia: the long journey to the fork in the road.
Immune Tolerance Induction to Factor IX through B Cell Gene Transfer: TLR9 Signaling Delineates between Tolerogenic and Immunogenic B Cells.
Immune tolerance induction with mycophenolate-mofetil in two children with haemophilia B and inhibitor.
Immune tolerance: critical issues of factor dose, purity and treatment complications.
Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates.
Immunoaffinity purification of factor IX (Christmas factor) by using conformation-specific antibodies directed against the factor IX-metal complex.
Immunoaffinity purification of factor IX from commercial concentrates and infusion studies in animals.
Immunoassays of factor IX antigen using monoclonal antibodies.
Immunochemical characterization of a polyclonal human antibody to factor IX.
Immunologic aberrations, HIV seropositivity and seroconversion rates in patients with hemophilia B.
Immunologic status of hemophilia patients treated with cryoprecipitate or lyophilized concentrate.
Immunological heterogeneity of haemophilia B: a multicentre study of 98 kindreds.
Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.
Implantable venous access devices in children with hemophilia: a report of low infection rates.
Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients.
Importance of factor-IX-dependent prothrombinase formation--the Josso pathway--in clotting plasma.
Importance of pharmacokinetics in the management of hemophilia.
Improved Induction of Immune Tolerance to Factor IX by Hepatic AAV-8 Gene Transfer.
Improved kinetics of rIX-FP, a recombinant fusion protein linking factor IX with albumin, in cynomolgus monkeys and hemophilia B dogs.
Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter.
Improvement in health-related quality of life in patients with haemophilia B treated with nonacog beta pegol, a new extended half-life recombinant FIX product.
Improvement in health-related quality of life with recombinant factor IX prophylaxis in severe or moderately severe haemophilia B patients: results from the BAX326 Pivotal Study.
In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in hemophilia B patients.
In vitro carboxylation of a blood coagulation factor IX precursor produced by recombinant-DNA technology.
In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B.
In vivo efficacy of human recombinant factor IX produced by the human hepatoma cell line HuH-7.
In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy.
In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
In vivo induction of regulatory T cells for immune tolerance in hemophilia.
In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients. The influence of reagents and standards.
Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
Incorporation of the factor IX Padua mutation into FIX-Triple improves clotting activity in vitro and in vivo.
Increased thrombin generation in a child with a combined factor IX and protein C deficiency.
Induced tolerance in hemophilia patients with antibodies against IX:C.
Induction of acquired factor IX inhibitors in cynomolgus monkey (Macaca fascicularis): a new primate model of hemophilia B.
Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure.
Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.
Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.
Influence of factor IX on overall plasma coagulability and fibrinolytic potential as measured by global assay: monitoring in haemophilia B.
Influence of source of phospholipids for APTT-based factor IX assays and potential consequences for the diagnosis of mild haemophilia B.
Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
Inherited bleeding disorders in dermatologic surgery.
Inhibitor antibodies to factor VIII and factor IX: management.
Inhibitor development in an elderly patient with severe factor IX deficiency being treated with ALPROLIX, a recombinant factor IX Fc fusion protein.
Inhibitor development in haemophilia B: an orphan disease in need of attention.
Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
Inhibitors in Hemophilia B.
Inhibitors to factor IX contain all IgG subclasses except IgG3.
Inhibitors-Recent insights.
Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX.
Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B.
Integration-deficient lentiviral vectors expressing codon-optimized R338LhFIX restore normal hemostasis in hemophilia B mice.
Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.
Intracranial meningioma in factor IX deficiency.
Intragenic Factor IX restriction site polymorphism in hemophilia B variants.
Intraosseous pseudotumour in a child with mild hemophilia B: report of a rare case and brief review of literature.
Intraspinal hematomas in hemophilia.
Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs.
Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis.
Iron studies in hemophilia.
Is haemophilia B less severe than haemophilia A?
Is the detection of factor IX inhibitors in hemophilia B orphan than factor VIII inhibitors in hemophilia A? A concise, systematic review.
Isolation and characterization of canine factor IX.
Isolation and characterization of factor IX Chapel Hill: comparison to normal human factor IX.
Isolation and characterization of human factor IX cDNA: identification of Taq I polymorphism and regional assignment.
Kinetics of factor IX activity differ from that of factor IX antigen in patients with haemophilia B receiving high-purity factor IX replacement.
Knee arthroplasty in hemophilic arthropathy.
Labor and delivery in a patient with hemophilia B.
Laboratory Comparison of the VisuLize IX Antigen Assay with the Asserachrome IX Antigen Assay.
Laboratory prediction of the carrier state in hemophilia B: role of replication of assays.
Laboratory testing for factor VIII and IX inhibitors in haemophilia: A review.
Lack of immune response to mouse IgG in previously untreated haemophilia A and haemophilia B patients treated with monoclonal antibody purified factor VIII and factor IX preparations.
Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma.
Lasting power of new clotting proteins.
Life threatening bleeding under adequate oral anticoagulation. Cases 4a, b.
Liposome-encapsulated DNA-mediated gene transfer and synthesis of human factor IX in mice.
Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice.
Liver-directed lentiviral gene therapy in a dog model of hemophilia B.
Living donor liver transplantation from an asymptomatic donor with mild coagulation factor IX deficiency: report of a case.
Long acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.
Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.
Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.
Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
Long-term phenotypic correction in factor IX knockout mice by using phiC31 integrase-mediated gene therapy.
Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.
Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
Long-Term Safety and Efficacy of Nonacog Beta Pegol (N9-GP) Administered for at Least 5 Years in Previously Treated Children with Hemophilia B.
Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study.
Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.
Low cost industrial production of coagulation factor IX bioencapsulated in lettuce cells for oral tolerance induction in hemophilia B.
Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.
Low-factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX.
Lupus anticoagulants associated inhibitor against factor IX in a young patient with haemophilia B.
Lysine 5 and phenylalanine 9 of the factor IX omega-loop interact with phosphatidylserine in a membrane-mimetic environment.
Magnetic Resonance Imaging of Mandibular Hemophilic Pseudotumor Associated With Factor IX Deficiency: Report of Case With Review of Literature.
Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
Management of haemophilia A with antibodies--the effect of combined treatment with factor VIII, hydrocortisone and cyclophosphamide.
Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates.
Management of joint bleeding in hemophilia.
Management of splenic trauma in the pediatric hemophiliac patient: Case series and review of the literature.
Management of third molar removal with a single dose of recombinant Factor IX (BeneFIX) and local measures in severe haemophilia B.
Management of third molar removal with doses of native plasma-derived factor IX (Octanine) and local measures in a female patient with severe hemophilia B: a case report.
Mapping of genes that control the antibody response to human factor IX in mice.
Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
Maternal low-level somatic mosaicism of Cys155Tyr of F9 in severe hemophilia B.
Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates.
Measurement of factor IX activity in plasma-derived and recombinant concentrates: insights from thrombin generation and activation-based assays.
Measurement of human factor IXa activity in an isolated factor X activation system.
Measurements of eftrenonacog alfa by 19 different combinations reagents/instrument: A single-centre study.
Medical management of extensive spinal epidural hematoma in a child with factor IX deficiency.
Membrane fusion FerA domains enhance adeno-associated virus vector transduction.
Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B.
Mesenteric venous thrombosis.
Microfluidic hemophilia models using blood from healthy donors.
Mild bleeding diathesis in a boy with combined severe haemophilia B (C(10400)-->T) and heterozygous factor V Leiden.
Mild haemophilia B from a novel missense mutation Ser350Ala of the F9 gene.
Missense mutations and evolutionary conservation of amino acids: evidence that many of the amino acids in factor IX function as "spacer" elements.
Missense mutations and the magnitude of functional deficit: the example of factor IX.
Moderate hemophilia B Leyden: identification by polymerase chain reaction, sequencing, and oligomer restriction.
Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.
Molecular analyses in hemophilia B families: identification of six new mutations in the factor IX gene.
Molecular analysis of 76 Chinese hemophilia B pedigrees and the identification of 10 novel mutations.
Molecular analysis of factor IX gene in an Iranian female with severe hemophilia B.
Molecular analysis of hemophilia B in Poland: 12 novel mutations of the factor IX gene.
Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor.
Molecular biology and genetics in cardiovascular research: highlights of 2002.
Molecular characterization of 16 hemophilia B families in Aragon, Spain.
Molecular characterization of factor IX gene mutations in 53 patients with haemophilia B in India.
Molecular characterization of hemophilia B in North Indian families: identification of novel and recurrent molecular events in the factor IX gene.
Molecular cloning of a cDNA encoding canine factor IX.
Molecular cloning of the gene for human anti-haemophilic factor IX.
Molecular defects of factor IX Chicago-2 (Arg 145----His) and prothrombin Madrid (Arg 271----cys): arginine mutations that preclude zymogen activation.
Molecular epidemiology of factor IX germline mutations in Mexican Hispanics: pattern of mutation and potential founder effects.
Molecular genetics and counselling in haemophilia.
Molecular pathology of haemophilia B in Turkish patients: identification of a large deletion and 33 independent point mutations.
Molecular pathology of haemophilia B.
Molecular pathology of haemophilia B: identification of five novel mutations including a LINE 1 insertion in Indian patients.
Molecular studies of haemophilia B in Sweden. Identification of patients with total deletion of the factor IX gene and without inhibitory antibodies.
Monitoring once-weekly recombinant factor IX prophylaxis in hemophilia B with thrombin generation assay and factor IX activity.
Monoclonal antibodies to factor IX: characterization and use in immunoassays for factor IX.
MonoFIX-VF, a new mono-component factor IX concentrate: a single-centre continuous-infusion study.
Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects.
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis.
Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Muscle as a target for supplementary factor IX gene transfer.
Muscle injection of rAAV/mFIX to secrete clotting factor IX corrects the hemorrhagic tendencies in hemophilia B mice.
Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
Mutant Macaque Factor IX T262A: A Tool for Hemophilia B Gene Therapy Studies in Macaques.
Mutation analysis impact on the genetic counseling of sporadic hemophilia B families.
Mutation of Factor IX Cys178 is intolerant and may cause severe hemophilia B.
Mutation rates in humans. II. Sporadic mutation-specific rates and rate of detrimental human mutations inferred from hemophilia B.
Mutational Profiles of F8 and F9 in a Cohort of Haemophilia A and Haemophilia B Patients in the Multi-ethnic Malaysian Population.
Mutations in the catalytic domain of human coagulation factor IX: rapid characterization by direct genomic sequencing of DNA fragments displaying an altered melting behavior.
Mutations in the factor IX gene (F9) during the past 150 years have relative rates similar to ancient mutations.
Myocardial infarction after factor IX therapy.
Myocardial infarction after FEIBA therapy in a hemophilia-B patient with a factor IX inhibitor.
Myocardial infarction during factor IX infusion in hemophilia B: case report and review of the literature.
Nanoparticles for the delivery of genes and drugs to human hepatocytes.
Nasal hemophilic pseudotumor: favorable response to radiotherapy.
Natural history study of factor IX deficiency with focus on treatment and complications (B-Natural).
Neonatal Gene Therapy for Hemophilia B by a Novel Adenovirus Vector Showing Reduced Leaky Expression of Viral Genes.
Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B.
Nephrotic syndrome associated with hypocomplementemia in a 4-year-old boy with hemophilia B.
Neurofibromatosis, factor IX deficiency, and rhabdomyosarcoma.
New and improved AAVenues: current status of hemophilia B gene therapy.
New developments in the management of moderate-to-severe hemophilia B.
New FACTOR IX linked marker alleles in African Haemophilia B patients.
New findings on animal diseases published since 2003. 1. Dogs.
No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
Non-invasive viral gene transfer of factor IX to colonic epithelial cells in hemophilia B mice.
Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities.
Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4).
Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients.
Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
Nonacog gamma, a novel recombinant factor IX with low factor IXa content for treatment and prophylaxis of bleeding episodes.
Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients.
Normal activated partial thromboplastin time in Chinese patients with mild hemophilia B.
Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene.
Novel missense mutation in the coagulation factor IX catalytic domain associated with severe haemophilia B--Factor IXDelhi.
Novel missense mutations in two patients with factor XI deficiency (Val271Leu and Tyr351Ser) and one patient with combined factor XI and factor IX deficiency (Phe349Val).
Novel molecules for the correction of factor Xa generation and phenotype in hemophilia.
Novel mutations in factor IX gene from western India with reference to their phenotypic and haplotypic attributes.
Nucleotide substitutions at the -6 position in the promoter region of the factor IX gene result in different severity of hemophilia B Leyden: consequences for genetic counseling.
Nullisomic deletion of the mcf.2 transforming gene in two haemophilia B patients.
Occult factor IX deficiency complicating the removal of third molars.
Off-pump myocardial revascularization in a diabetic patient with severe hemophilia B and impaired left ventricular function: hematological and operative strategies.
Omani experience with the use of factor IX Fc fusion protein.
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B.
Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials.
Optimal Immunofluorescent Staining for Human Factor IX and Infiltrating T Cells following Gene Therapy for Hemophilia B.
Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
Optimizing the treatment of haemophilia B: laboratory and clinical perspectives.
Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice.
Orthopaedic and surgical features in the management of patients with haemophilia.
Orthopedic Problems about the Ankle in Hemophilia.
Orthopedic surgery is possible in hemophilic patients with inhibitors.
Orthotopic liver transplantation for hepatitis C infection: the best Christmas present?
Orthotopic liver transplantation in hemophilia B: a case report.
Orthotopic liver transplantation totally corrects factor IX deficiency in hemophilia B.
Orthotropic live transplantation for cirrhosis from hepatitis C virus leads to correction of factor IX deficiency allowing for ankle arthroplasty without factor replacement in a patient with moderate haemophilia B.
Outcomes in total elbow arthroplasty in patients with haemophilia at the University of California, San Francisco: a retrospective review.
Partial deletion by illegitimate recombination of the factor IX gene in a haemophilia B family with two inhibitor patients.
Partial factor IX protein in a pedigree with hemophilia B due to a partial gene deletion.
Percutaneous coronary intervention in left main coronary artery disease in a patient with hemophilia B.
Percutaneous liver biopsy in hemophiliac children with chronic hepatitis C virus infection.
Performance of factor IX extended half-life product measurements in external quality control assessment programs.
Performances of an artificial reagent for the one-stage factor IX assay.
Perioperative factor IX replacement for surgical resection of a suprasellar astrocytoma in a child with severe haemophilia B.
Perioperative management of coronary artery bypass surgery in a patient with factor IX deficiency.
Perioperative replacement therapy in haemophilia B: An appeal to "B" more precise.
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX.
Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy.
Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
Persistent delivery of factor IX in mice: gene therapy for hemophilia using implantable microcapsules.
Persistent expression of canine factor IX in hemophilia B canines.
Persistent expression of hF.IX After tolerance induction by in utero or neonatal administration of AAV-1-F.IX in hemophilia B mice.
Pharmaceutical Approval Update.
Pharmacokinetic and pharmacodynamic properties of plasma-derived vs. recombinant factor IX in patients with hemophilia B: a prospective crossover study.
Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.
Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan.
Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Pharmacokinetics of a new human plasma-derived double virus inactivated and nanofiltered factor IX concentrate in previously treated severe or moderately severe haemophilia B patients.
Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.
Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation.
Pharmacokinetics of recombinant and plasma-derived factor IX products in pediatric patients with severe hemophilia B.
Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys.
Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis.
Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ?2%) haemophilia B.
Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
Pharmacokinetics, tissue distribution, excretion, and metabolite profiling of PEGylated rFIX (nonacog beta pegol, N9-GP) in rats.
Phase 3 Clinical Trial: Perioperative Use of Nonacog Gamma, a Recombinant Factor IX, in Previously Treated Patients With Moderate/Severe Hemophilia B.
Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.
Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B.
Phenotypic characterization of haemophilia B - Understanding the underlying biology of coagulation factor IX.
Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs.
Plasma support for surgery in a premature infant with factor IX deficiency.
Plasma-derived biological medicines used to promote haemostasis.
Point mutations in four hemophilia B patients from China.
Polymorphism of normal factor IX detected by mouse monoclonal antibodies.
Population pharmacokinetic modelling of factor IX activity after administration of recombinant factor IX in patients with haemophilia B.
Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B.
Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxis.
Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization.
Population-based surveillance of haemophilia and patient outcomes in Indiana using multiple data sources.
Portal vein delivery of viral vectors for gene therapy for hemophilia.
Possible absence of common polymorphisms in coagulation factor IX gene in Japanese subjects.
Possible association between cytomegalovirus infection and gastrointestinal bleeding in hemophiliac patients.
Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B.
Posttranslational modifications of recombinant myotube-synthesized human factor IX.
Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.
Potentially catastrophic bleeding disorders. Approach to diagnosis and management.
Practical Implications of Factor IX Gene Transfer for Individuals with Hemophilia B: A Clinical Perspective.
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes.
Preclinical and clinical progress in hemophilia gene therapy.
Preclinical development of plant-based oral immune modulatory therapy for haemophilia B.
Preclinical evaluation of a next-generation, subcutaneously administered, coagulation factor IX variant, dalcinonacog alfa.
Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B.
Prednisolone treatment induced temporary factor IX normalization in mild hemophilia B who required an epidural infiltration: A case report.
Prenatal diagnosis of haemophilia B by the use of polymerase chain reaction and direct sequencing.
Prenatal diagnosis of hemophilia B by an immunoradiometric assay of factor IX.
Preparation of factor IX deficient human plasma by immunoaffinity chromatography using a monoclonal antibody.
Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey.
Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B.
Prevention of cytotoxic T lymphocyte responses to factor IX-expressing hepatocytes by gene transfer-induced regulatory T cells.
Problems and solutions in laboratory testing for hemophilia.
Proceedings: Electroimmunoassay of human coagulation factor IX in the detection of variants of haemophilia B.
Production of biologically active human factor IX-Fc fusion protein in the milk of transgenic mice.
Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for hemophilia B.
Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
Progress towards gene therapy for haemophilia B.
PROLONG-9FP clinical development program - phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
Prolonged activity of factor IX as a monomeric Fc fusion protein.
Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide.
Properties of a highly purified human plasma factor IX:c therapeutic concentrate prepared by conventional chromatography.
Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.
Prophylaxis in factor IX deficiency product and patient variation.
Prophylaxis Using a Mixture of Plasma-Derived Activated Factor VII and Factor X (pdFVIIa/FX) in a Patient with Hemophilia B Complicated by Inhibitors and Allergy to Factor IX Concentrates: A Case Report.
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.
Pseudotumor in a patient with factor IX deficiency.
Pseudotumor of the Mandible as First Presentation of Hemophilia in a 2-Year-Old Male: A Case Report and Review of Jaw Pseudotumors of Hemophilia.
Purification and characterization of an abnormal factor IX (Christmas factor) molecule. Factor IX Chapel Hill.
Purification and characterization of rabbit factor IX and its existence as a two-chain factor IX alpha in circulating plasma.
Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor.
Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
Rabbit polyclonal antibodies against the calcium-dependent conformation of factor IX and their application in solid phase immunoradiometric assays.
Rational Clinical Dose Selection of Adeno-Associated Virus-Mediated Gene Therapy Based on Allometric Principles.
Real-World Analysis of Dispensed IUs of Coagulation Factor IX and Resultant Expenditures in Hemophilia B Patients Receiving Standard Half-life Versus Extended Half-life Products and Those Switching from Standard Half-life to Extended Half-life Products.
Real-world assay variability between laboratories in monitoring of recombinant factor IX Fc fusion protein activity in plasma samples.
Real-world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years.
Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
Recent advances in hemophilia B therapy.
Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia.
Recombinant Adeno-Associated Viral Vectors Expressing Human Coagulation FIX-E456H Variant in Hemophilia B Mice.
Recombinant factor IX (BAX326) in previously treated paediatric patients with haemophilia B: a prospective clinical trial.
Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study.
Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
Recombinant factor IX for clinical and research use.
Recombinant factor IX for the treatment of hemophilia B. Introduction.
Recombinant factor IX secreted by transduced human keratinocytes is biologically active.
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients.
Recombinant factor IX.
Recombinant factor VIII in hemophilia A: the Canadian experience.
Recombinant FIX Fc fusion protein activity assessment with the one-stage clotting assay: A multicenter, assessor-blinded, prospective study in Japan (J-Field Study).
Recombinant FIXFc: a novel therapy for the royal disease?
Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials.
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.
Recombinant versus plasma-derived factor IX in the treatment of hemophilia B: proceedings of a meeting held in June 2003.
Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter.
Recurrent mutations in the factor IX gene: founder effect or repeat de novo events. Investigation of the German haemophilia B population and review of de novo mutations.
Recurrent nonsense mutations at arginine residues cause severe hemophilia B in unrelated hemophiliacs.
Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs.
Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate.
Region of factor IXa protease domain that interacts with factor VIIIa: analysis of select hemophilia B mutants.
Regional localization on the human X chromosome and polymorphism of the coagulation factor IX gene (hemophilia B locus).
Regulation of human clotting factor IX cDNA expression in transgenic mice.
Regulation of human factor IX expression using doxycycline-inducible gene expression system.
Relationship of factor IX antigen and coagulant in hemophilia B patients and carriers.
Remarkable variation in the informativeness of RFLP markers linked to hemophilia B locus in Indian population groups: implication in the strategy for carrier detection.
Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors.
Repair of ventricular septal defect and aortic regurgitation associated with severe hemophilia B.
Repeated Diffuse Alveolar Hemorrhage in a Patient with Hemophilia B.
Replacing the first epidermal growth factor-like domain of factor IX with that of factor VII enhances activity in vitro and in canine hemophilia B.
Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors.
Resolution of spinal epidural haematoma without surgery in a haemophilic infant.
Results in three Australian haemophilia B patients with high-responding inhibitors treated with the Malmö model.
Results of a phase I/II open-label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients.
RFLPs of factor IX gene in Japanese haemophilia B families and gene deletion in two high-responder-inhibitor patients.
Ribosome readthrough accounts for secreted full-length factor IX in hemophilia B patients with nonsense mutations.
Risk factors associated with inhibitor development in Chinese patients with haemophilia B.
Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis.
Rituximab for adolescents with haemophilia and high titre inhibitors.
Robust ZFN-mediated genome editing in adult hemophilic mice.
Role of antigen-specific regulatory CD4(+)CD25(+) T cells in tolerance induction after neonatal IP administration of AAV-hF.IX.
Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
Role of the N-terminal EGF module of coagulation factor IX in activation of factors IX and X.
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B.
Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
Safety and effectiveness of Rixubis in patients with hemophilia B: a real-world, prospective, postmarketing surveillance study in South Korea.
Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
Safety and efficacy of high-purity concentrates in haemophiliac patients undergoing surgery by continuous infusion.
Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B.
Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis.
Safety and efficacy of purified factor IX concentrate and antifibrinolytic agents for dental extractions in hemophilia B.
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.
Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs.
Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study.
Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients.
Scanning by DOVAM-S detects all unique sequence changes in blinded analyses: evidence that the scanning conditions are generic.
Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B.
Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.
Sensitive solid phase enzyme immunoassay for factor IX antigen and classification of hemophilia B.
Sensitivity of the reaction time of the resonance thrombogram for factor VIII:C and factor IX deficiencies in the blood of dogs with haemophilia A or B.
Sensitivity of three activated partial thromboplastin time reagents to coagulation factor deficiencies.
Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs.
Sequence and structural properties of identical mutations with varying phenotypes in human coagulation factor IX.
Serologic evidence that factor IX inhibitor in the plasma of hemophilia B patients detects factor IX on normal red cells.
Severe factor VIII and factor IX deficiency in females.
Severe haemophilia B due to a 6 kb factor IX gene deletion including exon 4: non-homologous recombination associated with a shortened transcript from whole blood.
Simplifying surgery in haemophilia B: Low factor IX consumption and infrequent infusions in surgical procedures with rIX-FP.
Single nucleotide polymorphisms of the factor IX gene for linkage analysis in the southern Chinese population.
Single synonymous mutation in factor IX alters protein properties and underlies haemophilia B.
Single-dose pharmacokinetics of factor IX evaluated by model-independent methods.
Single-strand conformation polymorphism (SSCP) analysis of the molecular pathology of hemophilia B.
Six novel and three recurrent mutations in nine Austrian patients with hemophilia B.
Skeletal muscle-specific expression of human blood coagulation factor IX rescues factor IX deficiency mouse by AAV-mediated gene transfer.
Skewed X chromosome inactivation in fraternal female twins results in moderately severe and mild haemophilia B.
Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system.
Somatic mosaicism and compound heterozygosity in female hemophilia B.
Somatic mosaicism and female-to-female transmission in a kindred with hemophilia B (factor IX deficiency).
SOX3 is an X-linked gene related to SRY.
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations.
Spectrum of factor IX gene mutations causing haemophilia B from India.
Spectrum of hereditary coagulation factor deficiencies in eastern province, Saudi Arabia.
Splice junction mutations in factor IX gene resulting in severe hemophilia B.
Spontaneous disappearance of an IgA anti-factor IX inhibitor in a child with Christmas disease.
Spontaneous thoracolumbar hematomyelia secondary to hemophilia B in a cat.
Stable and high-level production of recombinant Factor IX in human hepatic cell line.
Stem cell-derived erythroid cells mediate long-term systemic protein delivery.
Strategies for Individualized Dosing of Clotting Factor Concentrates and Desmopressin in Hemophilia A and B.
Structural analysis of factor IX protein variants to predict functional aberration causing haemophilia B.
Structural and functional basis of the developmental regulation of human coagulation factor IX gene: factor IX Leyden.
Structural integrity of the gamma-carboxyglutamic acid domain of human blood coagulation factor IXa Is required for its binding to cofactor VIIIa.
Structure and function of factor IX: defects in haemophilia B.
Studies on Christmas disease: investigation and treatment of a familial acquired inhibitor of factor IX.
Subcutaneous factor IX administration to patients with hemophilia B.
Subcutaneous injection of factor IX for the treatment of haemophilia B.
Subperiosteal orbital hemorrhage as initial manifestation of Christmas disease (factor IX deficiency).
Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab(®) and desensitization therapy?
Successful in vivo propagation of factor IX-producing hepatocytes in mice: potential for cell-based therapy in haemophilia B.
Successful management of factor IX inhibitor-associated nephrotic syndrome in a hemophilia B patient.
Successful multi-modal immune tolerance induction for factor IX deficiency with inhibitors and allergic reactions.
Successful percutaneous coronary intervention for acute coronary syndrome in a patient with haemophilia B.
Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor.
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.
Suppression of factor IX antibody in hemophilia B by factor IX and cyclophosphamide.
Suppression of secondary antibody response by intravenous immunoglobulin in a patient with haemophilia b and antibodies.
Surgical excision of hemophilic pseudotumor of the ilium.
Surgical management of musculoskeletal involvement in hemophilic patients.
Surgical operation in hemophilia B. Use of factor IX concentrate.
Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.
Sustained and therapeutic delivery of factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis.
Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells.
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy.
Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.
Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells.
Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B.
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
SVA retrotransposition in exon 6 of the coagulation factor IX gene causing severe hemophilia B.
Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.
Synergy between transcription factors DBP and C/EBP compensates for a haemophilia B Leyden factor IX mutation.
Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
Systemic delivery of factor IX messenger RNA for protein replacement therapy.
Systemic Elimination of de novo Capsid Protein Synthesis from Replication-Competent AAV Contamination in the Liver.
T296----M, a common mutation causing mild hemophilia B in the Amish and others: founder effect, variability in factor IX activity assays, and rapid carrier detection.
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates.
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A.
Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice.
Technology evaluation: AAV factor IX gene therapy, Avigen Inc.
The abnormal factor IX of hemophilia B+ variants.
The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa.
The benefits of prophylaxis in patients with hemophilia B.
The carboxyl-terminal region of factor IX is essential for its secretion.
The carboxylation efficiency of the vitamin K-dependent clotting factors: studies with factor IX.
The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation.
The choice of plasma-derived clotting factor concentrates.
The clotting system - a major player in wound healing.
The Effect of Danazol Treatment on Factor IX Deficiency in Cats.
The evolution of recombinant factor replacement for hemophilia.
The factor IX gene as a model for analysis of human germline mutations: an update.
The female carrier of haemophilia--a problem for the anaesthetist.
The Future of Hemophilia Treatment: Longer-Acting Factor Concentrates versus Gene Therapy.
The gene therapy journey for hemophilia: are we there yet?
The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis.
The high frequency of the -6G-->A factor IX promoter mutation is the result both of a founder effect and recurrent mutation at a CpG dinucleotide.
The human genes for hemophilia A and hemophilia B flank the X chromosome fragile site at Xq27.3.
The limitation of factor IX coagulant activity determination in the diagnosis of hemophilia B carriers.
The liver as a target organ for gene therapy: state of the art, challenges, and future perspectives.
The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
The manufacturing process for recombinant factor IX.
The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
The molecular basis of haemophilia A and B.
The molecular genetics of hemophilia A and B in man. Factor VIII and factor IX deficiency.
The molecular pathology of haemophilia B. Fourth Wellcome Trust lecture.
The mutational spectrum of single base-pair substitutions causing human genetic disease: patterns and predictions.
The N-terminal epidermal growth factor-like domain of coagulation factor IX. Probing its functions in the activation of factor IX and factor X with a monoclonal antibody.
The novel mutation p.Asp315Tyr causes severe hemophilia B by impairing coagulation factor IX expression.
The pattern of factor IX germ-line mutation in Asians is similar to that of Caucasians.
The pattern of spontaneous germ-line mutation: relative rates of mutation at or near CpG dinucleotides in the factor IX gene.
The Pennsylvania hemophilia program 1973-1978.
The prevalence of AIDS-associated oral lesions in a cohort of patients with hemophilia.
The putative factor IX gene promoter in hemophilia B Leyden.
The rapid Bethesda assay is equivalent to the standard Bethesda assay for detection of factor IX inhibitors in patients with severe haemophilia B.
The rhesus macaque as an animal model for hemophilia B gene therapy.
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
The spectrum of human immunodeficiency virus infection in patients with factor IX deficiency (Christmas disease)
The stability of Christmas factor; a guide to the management of Christmas disease.
The treatment of flexion contracture of the knee using the Ilizarov technique in a child with haemophilia B.
The use of continuous infusion of factor concentrates in the treatment of hemophilia.
The use of epsilon-aminocaproic acid for the management of hemophilia in dental and oral surgery patients.
The use of factor IX concentrates in man: a 9-year experience of Scottish concentrates in the South-East of Scotland.
The use of prothrombin activating snake venoms to measure human prethrombin 2: absence of prethrombin 2 in serum.
The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate.
Therapeutic effects of hepatocyte transplantation on hemophilia B.
Therapeutic levels of factor IX expression using a muscle-specific promoter and adeno-associated virus serotype 1 vector.
Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B.
Three distinct point mutations in the factor IX gene of three Japanese CRM+ hemophilia B patients (factor IX BMNagoya 2, factor IX Nagoya 3 and 4).
Three novel PROC gene lesions causing protein C deficiency.
Three point mutations in the factor IX genes of five hemophilia B patients. Identification strategy using localization by altered epitopes in their hemophilic proteins.
Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
Thrombogenicity evaluation in 221 patients with haemophilia B treated with nonacog alfa.
Thrombogenicity of factor IX complex: in vivo investigation.
Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice.
Tissue distribution of rIX-FP after intravenous application to rodents.
Tolerance induction by viral in vivo gene transfer.
Toward a fluorescent single-strand conformation polymorphism technique that detects all mutations: F-DOVAM-S.
Towards gene therapy for haemophilia B using primary human keratinocytes.
Towards gene therapy for hemophilia B.
Transcriptional control of the factor IX gene: analysis of five cis-acting elements and the deleterious effects of naturally occurring hemophilia B Leyden mutations.
Transcriptional regulation of the human factor IX promoter by the orphan receptor superfamily factor, HNF4, ARP1 and COUP/Ear3.
Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP).
Transfusion-transmitted virus is not present in factor IX concentrates commonly used to treat haemophilia B.
Transgene expression levels and kinetics determine risk of humoral immune response modeled in factor IX knockout and missense mutant mice.
Translational Data from AAV-Mediated Gene Therapy of Hemophilia B in Dogs.
Translational Data from Adeno-Associated Virus-Mediated Gene Therapy of Hemophilia B in Dogs.
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
Treatment modalities for inherited factor IX deficiency and the implications of inherited bleeding disorders.
Treatment of a Hemophilia B Mouse Model with Platelet-Targeted Expression of Factor IX Padua.
Treatment of a patient with factor IX deficiency (hemophilia B) with coronary bypass surgery.
Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom.
Treatment of haemophilia B with purified Factor IX (PPSB).